<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): MARCH 30, 1998
-----------------------
IBAH, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
DELAWARE 0-19892 52-1670189
- ----------------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
</TABLE>
FOUR VALLEY SQUARE
512 TOWNSHIP LINE ROAD
BLUE BELL, PENNSYLVANIA 19422
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (215) 283-0770
-----------------
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS
------------
On March 30, 1998, IBAH, Inc., a Delaware corporation ("IBAH"), announced
by a press release that it had entered into a definitive Agreement and Plan of
Merger dated as of March 30, 1998 (the "Merger Agreement") with Omnicare, Inc.,
a Delaware corporation ("Omnicare"), and Impala Acquisition Corp., a Delaware
corporation and wholly-owned subsidiary of Omnicare formed solely for the
purpose of the transaction ("Omnicare Merger Sub"), which provides, among other
things, that, upon the terms and subject to conditions thereof, the Omnicare
Merger Sub will merge with and into IBAH (the "Merger"). IBAH will be the
surviving corporation and a wholly-owned subsidiary of Omnicare. The press
release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
In the Merger, each outstanding share of common stock, par value $.01 per
share ("IBAH Common Shares"), of IBAH will be converted into a fraction of a
share of the common stock, par value $1.00 per share ("Omnicare Common Shares"),
of Omnicare, equal to the Conversion Number (as defined below), plus cash in
lieu of receipt of fractional Omnicare Common Shares. In the Merger, each
outstanding share of preferred stock, par value $.01 per share ("IBAH Preferred
Shares" and, together with IBAH Common Shares, "IBAH Shares"), of IBAH will be
converted into a fraction of an Omnicare Common Share equal to three times the
Conversion Number.
The "Conversion Number" will be determined by the following formula: (1) if
the Omnicare Market Value (as defined below) is greater than $43.83, then the
Conversion Number is equal to $6.50 divided by the Omnicare Market Value; (2) if
the Omnicare Market Value is greater than $38.77 and less than or equal to
$43.83, then the Conversion Number is equal to 0.1483; (3) if the Omnicare
Market Value is greater than $34.85 and less than or equal to $38.77, then the
Conversion Number is equal to $5.75 divided by the Omnicare Market Value; (4) if
the Omnicare Market Value is greater than or equal to $30.30 and less than or
equal to $34.85, then the Conversion Number is equal to 0.1650; and (5) if the
Omnicare Market Value is less than $30.30, then, subject to the condition set
forth in the next sentence, the Conversion Number is equal to $5.00 divided by
the Omnicare Market Value. In the event that the Omnicare Market Value is less
than $30.30, Omnicare will have the right, by written notice to IBAH prior to
the effective time of the Merger, to adjust the Conversion Number to 0.1650,
provided that, upon receipt of such notice of adjustment, IBAH has the right, by
written notice to Omnicare, to elect to abandon the Merger and terminate the
Merger Agreement by action of its board of directors. "Omnicare Market Value"
means the average of the closing prices of an Omnicare Common Share on the New
York Stock Exchange, as reported in The Wall Street Journal, for the 15 trading
days immediately preceding the second trading day preceding the closing date of
the Merger.
In connection with the execution of the Merger Agreement, Omnicare and IBAH
entered into a Stock Option Agreement dated as of March 30, 1998 (the "Stock
Option Agreement") under which IBAH has granted Omnicare an option to purchase
up to 4,685,315 newly-issued IBAH Common Shares (approximately 19.9% of the
outstanding IBAH Common Shares as of March 30, 1998) at $5.75 per share if
certain triggering events occur.
In addition, in connection with the Merger Agreement, certain holders of
IBAH Common Shares and IBAH Preferred Shares entered into Voting Agreements
dated as of March 30, 1998 (the "Voting Agreements") pursuant to which they have
agreed with Omnicare, subject to certain exceptions, to vote such holders' IBAH
Shares in favor of the adoption of the Merger Agreement and approval of the
Merger, to vote against any contrary transaction, to grant to Omnicare an
irrevocable proxy to vote such IBAH Shares and not to dispose of such IBAH
Shares. IBAH Preferred Shares are entitled to vote on an as-converted basis with
IBAH Common Shares (giving the holders who agreed with Omnicare to vote in favor
of the Merger approximately 24.3% of the outstanding IBAH voting stock as of
March 30, 1998). Additionally, the remaining holders of IBAH Preferred Shares
have agreed that they will not consent to or otherwise facilitate any
transaction that is inconsistent with the Merger, but are not otherwise
restricted from disposing of any IBAH Shares held by them prior to the
stockholder vote on the Merger to the extent such disposition is in accordance
with applicable securities laws. The IBAH Preferred Shares held by such holders
represented approximately 4.6% of the outstanding IBAH voting stock as of March
30, 1998.
<PAGE>
Upon consummation of the Merger, IBAH Common Shares would cease to be
quoted on the Nasdaq National Market and would become eligible for termination
of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of
1934.
The foregoing summaries of the Merger Agreement and the Stock Option
Agreement (collectively, the "Agreements") are qualified in their entirety by
reference to the full text of such Agreements, a copy of which are filed
herewith.
Omnicare is a leading geriatric pharmaceutical care company serving
approximately 443,000 residents in more than 5,500 long-term care facilities in
37 states. Omnicare is a provider of professional pharmacy and related
consulting and data management services for long-term care, assisted living and
other institutional health care facilities. Omnicare also provides
comprehensive clinical research services for the pharmaceutical and
biotechnology industries through its Coromed subsidiary, which offers clinical
research services in the United States, Canada and Argentina.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
------------------------------------------------------------------
(c) Exhibits.
2.1 Agreement and Plan of Merger, dated as of March 30, 1998,
among IBAH, Omnicare and Impala Acquisition Corp.
2.2 Stock Option Agreement, dated as of March 30, 1998, between
IBAH and Omnicare.
99.1 Press Release dated March 31, 1998.
2
<PAGE>
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
IBAH, INC.
Date: April 2, 1998 By: /s/ Geraldine A. Henwood
----------------------------------------
Geraldine A. Henwood
Chief Executive Officer
<PAGE>
Exhibit Index
-------------
Exhibit
-------
2.1 Agreement and Plan of Merger and Contribution, dated as of March
30, 1998, among IBAH, Inc., Omnicare, Inc. and Impala Acquisition
Corp.
2.2 Stock Option Agreement, dated as of March 30, 1998, between IBAH,
Inc. and Omnicare, Inc.
99.1 Press Release dated March 31, 1998.
<PAGE>
EXHIBIT 2.1
- --------------------------------------------------------------------------------
AGREEMENT AND PLAN OF MERGER
among
OMNICARE, INC.
(a Delaware corporation),
IMPALA ACQUISITION CORP.
(a Delaware corporation)
and
IBAH, INC.
(a Delaware corporation)
MARCH 30, 1998
<PAGE>
TABLE OF CONTENTS
-----------------
<TABLE>
<CAPTION>
Section Page
- ------- ----
<S> <C>
ARTICLE I DEFINITIONS............................................................ 1
ARTICLE II THE PLAN OF MERGER.................................................... 9
Section 2.1. The Merger.......................................................... 9
Section 2.2. Effective Time...................................................... 9
Section 2.3. Effects of the Merger............................................... 9
Section 2.4. Certificate of Incorporation and Bylaws............................. 9
Section 2.5. Directors and Officers.............................................. 9
Section 2.6. Conversion or Cancellation of IBAH Shares........................... 9
Section 2.7. Exchange of IBAH Shares............................................. 11
Section 2.8. Options and Warrants................................................ 12
Section 2.9. Adjustments......................................................... 13
Section 2.10. Merger Subsidiary Capital Stock.................................... 13
Section 2.11. No Further Transfer of Shares...................................... 13
Section 2.12. Dissenting Shares.................................................. 13
ARTICLE III THE CLOSING.......................................................... 14
Section 3.1. Location, Date...................................................... 14
Section 3.2. Deliveries.......................................................... 14
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF IBAH................................ 14
Section 4.1. Corporate........................................................... 14
Section 4.2. Authorization....................................................... 14
Section 4.3. Validity of Contemplated Transactions............................... 15
Section 4.4. Capitalization and Stock Ownership.................................. 15
Section 4.5. Board Recommendation................................................ 16
Section 4.6. Proxy Statement..................................................... 16
Section 4.7. IBAH Disclosure Documents; Financial Statements..................... 16
Section 4.8. Absence of Undisclosed Liabilities.................................. 17
Section 4.9. Taxes............................................................... 17
Section 4.10. Title to Assets and Related Matters................................ 18
Section 4.11. Real Property...................................................... 19
Section 4.12. Subsidiaries....................................................... 19
Section 4.13. Legal Proceedings; Compliance with Law; Governmental Permits....... 19
Section 4.14. Contracts and Commitments.......................................... 20
Section 4.15. Employee Relations................................................. 20
Section 4.16. ERISA.............................................................. 20
Section 4.17. Patents, Trademarks, etc........................................... 22
Section 4.18. Absence of Certain Changes......................................... 22
Section 4.19. Corporate Records.................................................. 24
Section 4.20. Finder's Fees...................................................... 24
Section 4.21. Compliance with Healthcare Laws.................................... 24
Section 4.22. Board Approval..................................................... 25
Section 4.23. Pooling of Interests; Reorganization............................... 25
</TABLE>
<PAGE>
<TABLE>
<S> <C>
Section 4.24. Insurance................................................25
ARTICLE V REPRESENTATIONS AND WARRANTIES OF OMNICARE...................25
Section 5.1. Corporate.................................................25
Section 5.2. Authorization.............................................26
Section 5.3. Validity of Contemplated Transactions.....................26
Section 5.4. Capitalization and Stock Ownership........................26
Section 5.5. Board Recommendation......................................26
Section 5.6. Proxy Statement...........................................27
Section 5.7. Omnicare Disclosure Documents; Financial Statements.......27
Section 5.8. Absence of Undisclosed Liabilities........................27
Section 5.9. Absence of Certain Changes................................28
Section 5.10. Pooling of Interests; Reorganization.....................28
Section 5.11. Ownership of Merger Subsidiary; No prior Activities......28
Section 5.12. Compliance With Healthcare Laws..........................28
ARTICLE VI COVENANTS OF THE OMNICARE PARTIES AND IBAH..................29
Section 6.1. Proxy/Registration Statement..............................29
Section 6.2. HSR Act Filings...........................................29
Section 6.3. No Solicitation...........................................29
Section 6.4. Notification of Certain Matters...........................31
Section 6.5. Access to Information.....................................31
Section 6.6. Public Announcements......................................31
Section 6.7. Cooperation...............................................32
Section 6.8. Reorganization; Pooling...................................32
ARTICLE VII COVENANTS OF IBAH..........................................32
Section 7.1. Operation of the Business.................................32
Section 7.2. IBAH Stockholder Meeting..................................34
Section 7.3. Maintenance of the Assets.................................34
Section 7.4. Employees and Business Relations..........................34
Section 7.5. Rule 145 Affiliates.......................................34
Section 7.6. Expenses..................................................34
Section 7.7. Certain Tax Matters.......................................34
Section 7.8. Employment Arrangements...................................35
Section 7.9. State Anti-Takeover Law...................................35
ARTICLE VIII COVENANTS OF OMNICARE.....................................35
Section 8.1. Appointment to the Board of Directors of Omnicare.........35
Section 8.2. Expenses..................................................35
Section 8.3. Indemnification, Directors' and Officers' Insurance.......35
Section 8.4. Stock Exchange Listing....................................36
Section 8.5. Interim Financial Report..................................36
Section 8.6. Registration..............................................36
Section 8.7. Employee Benefit Plans....................................36
ARTICLE IX CONDITIONS PRECEDENT TO OBLIGATIONS OF ALL PARTIES..........36
Section 9.1. Legality..................................................36
Section 9.2. Registration Statement....................................37
Section 9.3. New York Stock Exchange...................................37
</TABLE>
<PAGE>
<TABLE>
<S> <C>
Section 9.4. Pooling...................................................37
Section 9.5. Approval by IBAH Stockholders.............................37
Section 9.6. Tax Opinions..............................................37
ARTICLE X CONDITIONS PRECEDENT TO OBLIGATIONS OF IBAH..................37
Section 10.1. Representations and Warranties...........................37
Section 10.2. Agreements, Conditions and Covenants.....................38
Section 10.3. Certificates.............................................38
Section 10.4. Material Adverse Effect..................................38
Section 10.5. Ancillary Documents......................................38
ARTICLE XI CONDITIONS PRECEDENT TO OBLIGATIONS OF THE OMNICARE
PARTIES...............................................................38
Section 11.1. Representations and Warranties...........................38
Section 11.2. Agreements, Conditions and Covenants.....................38
Section 11.3. Certificates.............................................38
Section 11.4. Required Consents........................................39
Section 11.5. Material Adverse Effect..................................39
Section 11.6. Ancillary Documents......................................39
Section 11.7. Consent of Holders of IBAH Preferred Shares and IBAH
Warrants..............................................................39
Section 11.8. Employment Agreements....................................39
ARTICLE XII TERMINATION................................................39
Section 12.1. Grounds for Termination..................................39
Section 12.2. Effect of Termination....................................41
ARTICLE XIII GENERAL MATTERS...........................................42
Section 13.1. Survival of Representations and Warranties...............42
Section 13.2. Contents of Agreement....................................42
Section 13.3. Amendment, Parties in Interest, Assignment, Etc..........42
Section 13.4. Interpretation...........................................42
Section 13.5. Notices..................................................43
Section 13.6. Governing Law............................................44
Section 13.7. Counterparts.............................................44
Section 13.8. Waivers..................................................44
Section 13.9. Modification.............................................44
Section 13.10. Enforcement of Agreement................................44
Section 13.11. Waiver of Jury Trial....................................44
Section 13.12. Severability............................................44
</TABLE>
<PAGE>
AGREEMENT AND PLAN OF MERGER
THIS AGREEMENT AND PLAN OF MERGER is made as of March 30, 1998 by and among
Omnicare, Inc., a Delaware corporation ("Omnicare"), IBAH Acquisition Corp., a
Delaware corporation (the "Merger Subsidiary," and together with Omnicare, the
"Omnicare Parties"), and IBAH, Inc., a Delaware corporation ("IBAH," and
together with the Omnicare Parties, the "Parties"). Certain other terms are
used herein as defined below in Article I or elsewhere in this Agreement.
Background
----------
This Agreement sets forth the terms and conditions under which the Merger
Subsidiary, which is a Wholly-Owned Subsidiary of Omnicare, will merge with and
into IBAH (the "Merger"). The Parties intend that (a) upon completion of the
Merger, IBAH will be a Wholly-Owned Subsidiary of Omnicare, (b) for federal
income tax purposes, the Merger will qualify as a reorganization within the
meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended, and
(c) for accounting purposes, the Merger will be accounted for as a pooling of
interests under United States generally accepted accounting principles ("GAAP").
Concurrently with the execution of this Agreement, and as an inducement to
Omnicare to enter into this Agreement, (i) certain stockholders of IBAH have
entered into a Voting Agreement, dated as of the date hereof (the "Voting
Agreement"), between IBAH and the respective stockholders named therein
providing, among other things, that such stockholders will vote in favor of the
Merger and (ii) IBAH and Omnicare have entered into the Option Agreement, dated
as of the date hereof (the "Stock Option Agreement"), pursuant to which IBAH has
granted Omnicare an option to purchase IBAH Common Shares under certain
circumstances.
Merger Subsidiary is a Wholly-Owned Subsidiary of Omnicare and has been
formed solely to facilitate the Merger and has conducted and will conduct no
business or activity other than in connection with the Merger.
Witnesseth
----------
NOW, THEREFORE, in consideration of the respective covenants contained
herein and intending to be legally bound hereby, the Parties hereto agree as
follows:
ARTICLE I
DEFINITIONS
For convenience, certain terms used in more than one part of this Agreement
are listed in alphabetical order and defined or referred to below (such terms as
well as any other terms defined elsewhere in this Agreement shall be equally
applicable to both the singular and plural forms of the terms defined).
<PAGE>
"Acquisition Proposal" is defined in Section 6.3.
"Affiliates" means, with respect to a particular Party, persons or entities
controlling, controlled by or under common control with that Party, as well as
any executive officers, directors and majority-owned entities of that Party and
of its other Affiliates.
"Agreement" means this Agreement and the Exhibits and Disclosure Schedules
hereto.
"Assets" means, with respect to Omnicare or IBAH, as shown by the context
in which used, all of the assets, properties, goodwill and rights of every kind
and description, real and personal, tangible and intangible, wherever situated
and whether or not reflected in such Party's most recent financial statements,
that are owned or possessed by such Party and its Subsidiaries, taken as a
whole.
"Assumed Option" is defined in Section 2.8(a).
"Benefit Plan" means all employee benefit, health, welfare, supplemental
unemployment benefit, bonus, pension, profit sharing, deferred compensation,
severance, incentive, stock compensation, stock purchase, retirement,
hospitalization insurance, medical, dental, legal, disability, fringe benefit
and similar plans, programs, arrangements or practices, including, without
limitation, each "employee benefit plan" as defined in Section 3(3) of ERISA.
"Business" means with respect to Omnicare or IBAH, as shown by the context
in which used, the entire business and operations of such Party and its
Subsidiaries, taken as a whole.
"Certificate of Merger" is defined in Section 2.2.
"Certificates" is defined in Section 2.7(a).
"Charter Documents" means an entity's certificate or articles of
incorporation, certificate defining the rights and preferences of securities,
articles of organization, general or limited partnership agreement, certificate
of limited partnership, joint venture agreement or similar document governing
the entity.
"Closing" is defined in Section 3.1.
"Closing Date" is defined in Section 3.1.
"Code" is defined in Section 4.9(a).
"Confidentiality Agreement" is defined in Section 6.5(b).
"Contract" means any written or oral contract, agreement, letter of intent,
agreement in principle, lease, instrument or other commitment that is binding on
any Person or its property under applicable Law.
2
<PAGE>
"Conversion Number" is defined in Section 2.6(b).
"Copyrights" means registered copyrights, copyright applications and
unregistered copyrights.
"Court Order" means any judgment, decree, injunction, order or ruling of
any federal, state, local or foreign court or governmental or regulatory body or
authority, or any arbitrator that is binding on any Person or its property under
applicable Law.
"Default" means (i) a breach, default or violation, (ii) the occurrence of
an event that with or without the passage of time or the giving of notice, or
both, would constitute a breach, default or violation or (iii) with respect to
any Contract, the occurrence of an event that with or without the passage of
time or the giving of notice, or both, would give rise to a right of
termination, renegotiation or acceleration or a right to receive damages or a
payment of penalties.
"DGCL" means the Delaware General Corporation Law, as amended.
"Disclosure Schedules" means the IBAH Disclosure Schedule.
------------------------
"Effective Time" is defined in Section 2.2.
"Encumbrances" means any lien, mortgage, security interest, pledge,
restriction on transferability, defect of title or other claim, charge or
encumbrance of any nature whatsoever on any property or property interest.
"Environmental Condition" means any condition or circumstance, including
the presence of Hazardous Substances, whether created by any IBAH Company or by
any third party, which does or would (i) require assessment, investigation,
abatement, correction, removal or remediation under any Environmental Law, (ii)
give rise to any civil or criminal Liability under any Environmental Law, (iii)
create or constitute a public or private nuisance or (iv) constitute a violation
of or non-compliance with any Environmental Law.
"Environmental Law" means all Laws, Court Orders, principles of common
law, and permits, licenses, registrations, approvals or other authorizations of
any Governmental Authority relating to Hazardous Substances, pollution,
protection of the environment or human health.
"ERISA" means the Employee Retirement Income Security Act of 1974, as
amended.
"Exchange Act" means the Securities Exchange Act of 1934, as amended.
"Exchange Agent" is defined in Section 2.7(a).
"Existing Option" is defined in Section 2.8(a).
3
<PAGE>
"GAAP" is defined above in the Background.
"Governmental Authority" means any federal, state, local, municipal or
foreign or other government or governmental agency or body.
"Governmental Permit" is defined in Section 4.13(c).
"Hazardous Substances" means any material, waste or substance (including,
without limitation, any product) that may or could pose a hazard to the
environment or human health or safety including, without limitation, (i) any
"hazardous substances" as defined by the Comprehensive Environmental Response,
Compensation and Liability Act, 42 U.S.C. (S)(S) 9601 et seq. and its
-- ----
implementing regulations, (ii) any "extremely hazardous substance," "hazardous
chemical" or "toxic chemical" as those terms are defined by the Emergency
Planning and Community Right-to-Know Act, 42 U.S.C. (S)(S) 11001 et seq. and its
-- ----
implementing regulations, (iii) any "hazardous waste," as defined under the
Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery
Act, 42 U.S.C. (S)(S) 6901 et seq. and its implementing regulations (iv) any
-- ----
"pollutant," as defined under the Water Pollution Control Act, 33 U.S.C. (S)(S)
1251 et seq. and its implementing regulations as any of such Laws in clauses (i)
-- ----
through (iv) may be amended from time to time, and (v) any material, substance
or waste regulated under any Laws or Court Orders that currently exist or that
may be enacted, promulgated or issued in the future by any Governmental
Authority concerning protection of the environment, pollution, health or safety
or the public welfare.
"Holder" means a recordholder, as of the Effective Time, of an outstanding
certificate or certificates that immediately prior to the Effective Time
represented IBAH Shares.
"HSR Act" means the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
as amended.
"IBAH" is defined above in the Preamble.
"IBAH Assets" means the Assets of IBAH.
"IBAH Balance Sheet" is defined in Section 4.7.
"IBAH Balance Sheet Date" is defined in Section 4.7.
"IBAH Benefit Plan" is defined in Section 4.16(a).
"IBAH Business" means the Business of IBAH.
"IBAH Common Shares" is defined in Section 2.6(a).
"IBAH Common Stock" means the common stock, par value $0.01 per share, of
IBAH.
"IBAH Companies" means IBAH and any IBAH Subsidiaries.
4
<PAGE>
"IBAH Convertible Preferred Stock" is defined in Section 4.4.
"IBAH Disclosure Documents" is defined in Section 4.7.
"IBAH Disclosure Schedule" means the Disclosure Schedule containing
------------------------
information relating to IBAH pursuant to Article IV and other provisions hereof
that has been provided to the other Parties on the date hereof.
"IBAH's knowledge" or "knowledge of IBAH" with reference to any item means
that which an executive officer or director of IBAH actually knows or should
have known given such person's office and industry standards.
"IBAH Personnel" is defined in Section 4.21(a).
"IBAH Preferred Shares" is defined in Section 2.6(a).
"IBAH Required Consents" is defined in Section 4.3.
"IBAH Shares" is defined in Section 2.6(a).
"IBAH Stockholder Meeting" is defined in Section 7.2.
"IBAH Subsidiary" means any Subsidiary of IBAH.
"IBAH 10-K" is defined in Section 4.10.
"IBAH Warrants" means any warrants to purchase IBAH Common Stock that are
outstanding immediately prior to the Closing.
"IBAH Welfare Plan" is defined in Section 4.16(f).
"Intellectual Property" means any Copyrights, Patents, Trademarks,
technology, licenses, trade secrets, computer software and other intellectual
property.
"Law" means any statute, law, ordinance, regulation, order, rule, common
law principles or consent agreements of any Governmental Authority, including,
without limitation, those covering environmental, energy, safety, health,
transportation, bribery, recordkeeping, zoning, antidiscrimination, antitrust,
wage and hour, and price and wage control matters.
"Liability" means any direct or indirect liability, indebtedness,
obligation, expense, claim, loss, damage, deficiency, guaranty or endorsement of
or by any Person.
"Litigation" means any lawsuit, action, arbitration, administrative or
other proceeding, criminal prosecution or governmental investigation or inquiry.
5
<PAGE>
"Material Adverse Effect" means a fact or event which has had or is
reasonably likely to have a material adverse effect on the Assets, Business,
financial condition or results of operations of Omnicare and its Subsidiaries
taken as a whole or IBAH and its Subsidiaries taken as a whole, as indicated by
the context in which used, and when used with respect to representations,
warranties, conditions, covenants or other provisions hereof means the
individual effect of the situation to which it relates and also the aggregate
effect of all similar situations unless the context indicates otherwise.
"Merger" is defined above in the Background.
"Merger Consideration" is defined in Section 2.6(g).
"Merger Subsidiary" is defined above in the Preamble.
"NYSE" means the New York Stock Exchange.
"Omnicare" is defined above in the Preamble.
"Omnicare Assets" means the Assets of Omnicare.
"Omnicare Balance Sheet" is defined in Section 5.7.
"Omnicare Balance Sheet Date" is defined in Section 5.7.
"Omnicare Business" means the Business of Omnicare.
"Omnicare Common Stock" means the common stock, par value $1.00 per share,
of Omnicare.
"Omnicare Companies" mean Omnicare and any Omnicare Subsidiaries.
"Omnicare Disclosure Documents" is defined in Section 5.7.
"Omnicare's knowledge" or "knowledge of Omnicare" with reference to any
item means that which an executive officer or director of Omnicare actually
knows or should have known given such person's office and industry standards.
"Omnicare Market Value" is defined in Section 2.6(f).
"Omnicare Parties" is defined above in the Preamble.
"Omnicare Shares" means shares of Omnicare Common Stock.
"Omnicare Sub Common Stock" is defined in Section 5.4.
"Omnicare Subsidiary" means any Subsidiary of Omnicare.
6
<PAGE>
"Omnicare Warrants" means warrants to purchase Omnicare Common Stock.
"Ordinary course" or "ordinary course of business" means the ordinary
course of business.
"Parties" is defined above in the Preamble.
"Party Representatives" is defined in Section 6.5(b).
"Patents" means patents, patent applications, reissue patents, patents of
addition, divisions, renewals, continuations, continuations-in-part,
substitutions, additions and extensions of any of the foregoing.
"Person" means any natural person, corporation, partnership, limited
liability company, proprietorship, association, trust or other legal entity.
"Post-Signing Returns" is defined in Section 7.7.
"Proxy/Registration Statement" is defined in Section 6.1(a).
"Proxy Statement" is defined in Section 6.1(a).
"Registration Statement" is defined in Section 6.1(a).
"Regulation" means any federal, state, local or foreign rule or regulation.
"SEC" means the Securities and Exchange Commission.
"Securities Act" means the Securities Act of 1933, as amended.
"Securities Act Affiliates" is defined in Section 7.5.
"Smith Barney" means Salomon Smith Barney Inc.
"Stock Option Agreement" is defined in the Background section above.
"Subsidiary" means any corporation or other legal entity of which Omnicare
or IBAH, as the case may be (either above or through or together with any other
Subsidiary) owns, directly or indirectly, more than 50% of the stock or other
equity interests the holders of which are generally entitled to vote for the
election of directors or other governing body of such corporation or other
entity.
"Surviving Corporation" is defined in Section 2.1.
"Taxes" is defined in Section 4.9(a).
7
<PAGE>
"Tax Return" is defined in Section 4.9(a).
"Termination Date" means October 31, 1998.
"Trademarks" means registered trademarks, registered service marks,
trademark and service mark applications and unregistered trademarks and service
marks.
"Transaction Documents" means this Agreement, the Employment Agreements,
the Voting Agreement and the Stock Option Agreement.
"Transactions" means the Merger, the exchange of IBAH Shares for Omnicare
Shares, the assumption by Omnicare of the Existing Options, the exchange of IBAH
Warrants for Omnicare Warrants, and the other transactions contemplated by the
Transaction Documents.
"Voting Agreement" is defined above in the Background.
"Wholly-Owned Subsidiary" means any Subsidiary in which all of the stock or
other equity interests is owned, directly or indirectly, by Omnicare or IBAH, as
the case may be.
8
<PAGE>
ARTICLE II
THE PLAN OF MERGER
Section 2.1. The Merger. Upon the terms and subject to the conditions
----------
hereof, and in accordance with the relevant provisions of the DGCL, the Merger
Subsidiary shall be merged with and into IBAH. Following the Merger, IBAH shall
continue as the surviving corporation (the "Surviving Corporation") and shall
continue its existence under the Laws of the State of Delaware, and the separate
corporate existence of the Merger Subsidiary shall cease.
Section 2.2. Effective Time. As soon as practicable, but in any event
--------------
within one business day after the satisfaction or waiver of all conditions to
the Merger, IBAH and the Merger Subsidiary shall file with the Secretary of
State of the State of Delaware a certificate of merger (the "Certificate of
Merger") in such form as is required by the DGCL. The Merger shall become
effective at such time as the Certificate of Merger is so filed (the "Effective
Time").
Section 2.3. Effects of the Merger. The Merger shall have the effects
---------------------
set forth in Section 259 of the DGCL.
Section 2.4. Certificate of Incorporation and Bylaws. The Certificate
---------------------------------------
of Incorporation of the Merger Subsidiary as in effect immediately prior to the
Effective Time shall be the initial Certificate of Incorporation of the
Surviving Corporation. The bylaws of the Merger Subsidiary as in effect
immediately prior to the Effective Time shall be the initial bylaws of the
Surviving Corporation.
Section 2.5. Directors and Officers. The directors of Merger Subsidiary
----------------------
as in office as of immediately prior to the Effective Time shall be the initial
directors of the Surviving Corporation. The officers of IBAH as in office as of
immediately prior to the Effective Time shall be the initial officers of the
Surviving Corporation. Such persons shall hold such positions as directors and
officers until their successors are elected or appointed in accordance with the
Certificate of Incorporation and the bylaws of the Surviving Corporation.
Section 2.6. Conversion or Cancellation of IBAH Shares.
-----------------------------------------
(a) Each share of IBAH Common Stock (an "IBAH Common Share") and each
share of IBAH Convertible Preferred Stock (an "IBAH Preferred Share," and
together with an IBAH Common Share, an "IBAH Share") that, immediately prior to
the Effective Time, is held by IBAH as treasury stock shall be canceled, and no
consideration shall be delivered with respect thereto.
(b) Each IBAH Common Share outstanding immediately prior to the
Effective Time shall by virtue of the Merger and without any action on the part
of the Holder thereof, be converted into the right to receive a number (the
"Conversion Number") of Omnicare Shares as set forth below, except as otherwise
provided in Sections 2.6(a), 2.6(e) or 2.7:
9
<PAGE>
(1) If the Omnicare Market Value is greater than $43.83, then the
Conversion Number is equal to $6.50 divided by the Omnicare Market Value;
(2) If the Omnicare Market Value is greater than $38.77 and less than
or equal to $43.83, then the Conversion Number is equal to 0.1483;
(3) If the Omnicare Market Value is greater than $34.85 and less than
or equal to $38.77, then the Conversion Number is equal to $5.75 divided by the
Omnicare Market Value;
(4) If the Omnicare Market Value is greater than or equal to $30.30
and less than or equal to $34.85, then the Conversion Number is equal to 0.1650;
(5) If the Omnicare Market Value is less than $30.30, then, subject
to Section 2.6(c) below, the Conversion Number is equal to $5.00 divided by the
Omnicare Market Value.
(c) If the Omnicare Market Value is less than $30.30, then Omnicare
shall have the right, by written notice to IBAH prior to the Effective Time, to
adjust the Conversion Number to 0.1650; provided, however, that upon the receipt
of such notice of adjustment, IBAH shall have the right, by written notice to
Omnicare (the "Termination Notice"), to elect to abandon the Merger and
terminate this Agreement by action of its Board of Directors, which termination
shall occur at 5:00 p.m., Cincinnati, Ohio time, two business days after the
Termination Notice.
(d) Each IBAH Preferred Share outstanding immediately prior to the
Effective Time shall by virtue of the Merger and without any action on the part
of the Holder thereof, be converted into the right to receive a number of
Omnicare Shares equal to three times the Conversion Number, except as otherwise
provided in Sections 2.6(a), 2.6(e), 2.7 or 2.12.
(e) No fractional Omnicare Shares shall be issued in the Merger.
Each Holder who would otherwise be entitled to receive a fractional share shall
be entitled to receive, in lieu thereof, an amount in cash determined by
multiplying the Omnicare Market Value by the fraction of an Omnicare Share to
which such Holder would otherwise have been entitled.
(f) For purposes of this Section 2.6, the term "Omnicare Market
Value" shall mean the average of the closing prices of the Omnicare Shares on
the New York Stock Exchange, as reported in The Wall Street Journal, for the 15
trading days immediately preceding the second trading day preceding the Closing
Date.
(g) The consideration to be received by the Holders in respect of
each IBAH Share pursuant to this Section 2.6 is hereinafter referred to as the
"Merger Consideration."
10
<PAGE>
Section 2.7. Exchange of IBAH Shares.
-----------------------
(a) Prior to the Effective Time, Omnicare shall appoint an agent (the
"Exchange Agent") for the purpose of exchanging certificates that immediately
prior to the Effective Time represented IBAH Shares (the "Certificates") for the
Merger Consideration. Promptly after the Effective Time, Omnicare will send, or
will cause the Exchange Agent to send, to each Holder (other than IBAH and any
Subsidiary of IBAH) a letter of transmittal for use in such exchange. Omnicare
will make available to the Exchange Agent, as needed, the aggregate Merger
Consideration to be paid in respect of the IBAH Shares.
(b) Each Holder, upon surrender to the Exchange Agent of a
Certificate or Certificates together with a properly completed letter of
transmittal covering such Certificates, will be entitled to receive the Merger
Consideration payable in respect of the IBAH Shares formerly represented
thereby, after giving effect to any required withholding Tax. Until so
surrendered, each Certificate shall, after the Effective Time, represent for all
purposes, only the right to receive such Merger Consideration. In no event will
a Holder be entitled to interest on the Merger Consideration.
(c) If any portion of the Merger Consideration is to be paid to a
Person other than the registered holder of the IBAH Shares formerly represented
by the Certificate or Certificates surrendered in exchange for the Merger
Consideration, it shall be a condition to such payment that the Certificate or
Certificates so surrendered shall be properly endorsed or otherwise be in proper
form for transfer and that the Person requesting such payment shall pay to the
Exchange Agent any transfer or other Taxes required as a result of such payment
to a Person other than the registered holder of such IBAH Shares or establish to
the satisfaction of the Exchange Agent that such Tax has been paid or is not
payable.
(d) Any portion of the Merger Consideration made available to the
Exchange Agent pursuant to this Section 2.7 that remains unclaimed by the
Holders six months after the Effective Time shall be returned to Omnicare, upon
demand, and any such Person who has not exchanged his Certificate or
Certificates for the Merger Consideration in accordance with this Article II
prior to that time shall thereafter look only to Omnicare for payment of the
Merger Consideration. Notwithstanding the foregoing, Omnicare shall not be
liable to any Person for any amount paid to a public official pursuant to
applicable abandoned property Laws. Any amounts remaining unclaimed under this
Article II two years after the Effective Time (or such earlier date immediately
prior to such time as such amounts would otherwise escheat to or become property
of any governmental entity) shall, to the extent permitted by applicable Law,
become the property of Omnicare free and clear of any claims or interest of any
Person previously entitled thereto.
(e) No dividends or other distributions with respect to securities of
Omnicare constituting part of the Merger Consideration shall be paid to the
Holder of any unsurrendered Certificates until such Certificates are surrendered
as provided in this Article II. Upon such surrender, there shall be paid,
without interest, to the Person in whose name the Certificates representing the
securities of Omnicare into which such IBAH Shares were converted are
11
<PAGE>
registered, all dividends and other distributions payable in respect of such
securities on a date subsequent to, and in respect of a record date after, the
Effective Time, less the amount of withholding Taxes which may be required
thereon.
(f) If any Certificate shall have been lost, stolen or destroyed,
upon the making of an affidavit of that fact by the person claiming such
Certificate to be lost, stolen or destroyed and, if required by Omnicare, the
posting by such person of a bond in such reasonable amount as Omnicare may
direct as indemnity against any claim that may be made against it with respect
to such Certificate, the Exchange Agent shall issue in exchange for such lost,
stolen or destroyed Certificate the consideration provided for, and in
accordance with the procedures set forth, in this Article II and, if applicable,
any unpaid dividends and distributions with respect to securities of Omnicare
constituting part of the Merger Consideration deliverable with respect thereof
and any cash in lieu of fractional shares, in each case pursuant to this
Agreement.
Section 2.8. Options and Warrants.
--------------------
(a) At the Effective Time, Omnicare shall assume IBAH's rights and
obligations under each of the outstanding stock options previously granted by
IBAH to certain of its employees, directors and consultants that are outstanding
immediately prior to the Effective Time (each such stock option existing
immediately prior to the Effective Time is referred to herein as an "Existing
Option" and each such assumed stock option existing immediately after the
Effective Time is referred to herein as an "Assumed Option"). Under each
Assumed Option, the optionee shall have the right to receive from Omnicare, in
accordance with the terms and subject to the conditions of the Existing Option,
the Merger Consideration that such optionee would have been entitled to receive
had the optionee exercised his or her Existing Option immediately prior to the
Effective Time, but only in accordance with the terms and conditions of the
Existing Option (including payment of the aggregate exercise price thereof).
Except as provided in this Section 2.8(a), the Assumed Option shall not give the
optionee any additional benefits that the holder thereof did not have under the
Existing Option; provided, however, that the terms of such Existing Options
shall govern the vesting thereof, including, if applicable, any vesting of
Existing Options as a result of the Merger. Each Assumed Option shall
constitute a continuation of the Existing Option, substituting Omnicare for IBAH
and, in the case of employees, employment by an Omnicare Company for employment
by an IBAH Company. Notwithstanding the foregoing, the terms of any Assumed
Option shall be such that the substitution of the Assumed Option for the
Existing Option would not constitute a modification of the Existing Option
within the meaning of Section 424(h)(3) of the Code and the Regulations
promulgated thereunder.
(b) If and to the extent required by the terms of the plans governing
the Existing Options or pursuant to the terms of any Existing Option granted
thereunder, IBAH shall use reasonable efforts to obtain the consent of each
holder of outstanding Existing Options to the treatment of the Existing Options
provided in Section 2.8(a).
(c) Each IBAH Warrant that is outstanding immediately prior to the
Effective Time and that does not expire at the Effective Time by the terms
thereof shall, by virtue of the
12
<PAGE>
Merger and pursuant to the terms of the IBAH Warrant or with the consent of the
majority of the holders thereof, be converted into and exchanged for a Omnicare
Warrant exercisable for the Conversion Number of Omnicare Shares for each share
of IBAH Common Stock for which the IBAH Warrant is exercisable immediately prior
to the Effective Time, at an exercise price per Omnicare Share that has been
adjusted in accordance with the terms of the IBAH Warrant converted hereunder as
a result of the Merger. Except as provided in this Section 2.8(c), the Omnicare
Warrants shall have the terms and conditions of the IBAH Warrants converted
hereunder. At the Effective Time, the Omnicare Parties shall make available to
any holders of IBAH Warrants converted hereunder a new warrant evidencing the
Omnicare Warrant.
Section 2.9. Adjustments. If at any time during the period between the
-----------
date of this Agreement and the Effective Time, any change in the outstanding
shares of capital stock of IBAH or Omnicare shall occur by reason of any
reclassification, recapitalization, stock split or combination, exchange or
readjustment of shares, or any stock dividend thereon with a record date during
such period or any similar event, this Article II shall be appropriately
adjusted.
Section 2.10. Merger Subsidiary Capital Stock. Each share of capital
-------------------------------
stock of the Merger Subsidiary issued and outstanding immediately prior to the
Effective Time shall be converted, by virtue of the Merger, into one share of
common stock of the Surviving Corporation.
Section 2.11. No Further Transfer of Shares. After the Effective Time,
-----------------------------
there shall be no transfers of IBAH Shares that were outstanding immediately
prior to the Effective Time on the stock transfer books of the Surviving
Corporation. If, after the Effective Time, Certificates are presented to the
Surviving Corporation for transfer, they shall be canceled and exchanged for the
respective Merger Consideration as provided in this Article II. At the
Effective Time, the stock ledger of IBAH shall be closed.
Section 2.12. Dissenting Shares. Notwithstanding Section 2.6, the IBAH
-----------------
Preferred Shares that are issued and outstanding immediately prior to the
Effective Time and that are held by Holders who did not vote in favor of the
Merger and who comply with all of the relevant provisions of Section 262 of the
DGCL (the "Dissenting Shares") shall not be converted into the right to receive
the Merger Consideration, unless and until such Holders shall have waived in
writing or failed to perfect or shall have effectively withdrawn or lost their
rights to appraisal under the DGCL; and any such Holder shall have only such
rights in respect of the Dissenting Shares owned by them as are provided by
Section 262 of the DGCL. If any such Holder shall have waived in writing or
failed to perfect or shall have effectively withdrawn or lost such right, such
Holder's Dissenting Shares shall thereupon be deemed to have been converted into
and to have become exchangeable, as of the Effective Time, for the right to
receive the Merger Consideration without any interest thereon, pursuant to the
terms of Section 2.6. Prior to the Effective Time, IBAH will not, except with
the prior written consent of Omnicare, voluntarily make any payment with respect
to, or settle or offer to settle, any claim made by the stockholders owning the
Dissenting Shares.
13
<PAGE>
ARTICLE III
THE CLOSING
Section 3.1. Location, Date. The closing for the Transactions (the
--------------
"Closing") shall be held at the offices of Dewey Ballantine LLP in New York, New
York at 9:00 a.m. (local time) as promptly as practicable (and in any event
within one business day) after satisfaction or waiver of the conditions to the
consummation of the Transactions set forth in Articles IX, X and XI. The date
on which the Closing occurs is referred to herein as the "Closing Date."
Section 3.2. Deliveries. At the Closing,
----------
(a) the Merger Subsidiary and IBAH shall deliver or cause to be
delivered to the Secretary of State of the State of Delaware a duly executed
Certificate of Merger as required under Section 263 of DGCL and the Parties
shall take all such other and further actions as may be required by the DGCL and
any other applicable Law to make the Merger effective upon the terms and subject
to the conditions hereof; and
(b) the Parties shall also deliver to each other the respective
agreements and other documents and instruments specified with respect to them in
Articles IX, X and XI.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF IBAH
IBAH hereby represents and warrants to the Omnicare Parties as follows,
except as otherwise set forth in the IBAH Disclosure Schedule (items disclosed
------------------------
in one Section of such Schedule shall apply to all other Sections unless the
context indicates otherwise):
Section 4.1. Corporate. Each IBAH Company is a corporation duly
---------
organized, validly existing and in good standing under the Laws under which it
was incorporated. Each IBAH Company is qualified to do business as a foreign
corporation in any jurisdiction where it is required to be so qualified, except
where the failure to so qualify would not have a Material Adverse Effect. The
Charter Documents and bylaws of each IBAH Company (all of which have been
delivered or made available to Omnicare) have been duly adopted and are current,
correct and complete. Each IBAH Company has all necessary corporate power and
authority to own, lease and operate its part of the IBAH Assets and to carry on
its part of the IBAH Business as it is now being conducted.
Section 4.2. Authorization. IBAH has the requisite corporate power and
-------------
authority to execute and deliver the Transaction Documents to which it is a
party and to perform the Transactions to be performed by it. Such execution,
delivery and performance by IBAH have been duly authorized by all necessary
corporate action, other than that the consummation of the Merger is subject to
the approval of the holders of a majority of the outstanding IBAH Shares, voting
as a single class and the consent of the holders of a majority of the
outstanding IBAH Preferred Shares to the conversion of the IBAH Preferred Shares
into the right to receive
14
<PAGE>
Omnicare Shares as contemplated by Article II hereof, which are the only
consents or approvals of holders of IBAH Shares required for the consummation of
the Transactions. IBAH has received such consents from the holders of all
outstanding IBAH Preferred Shares. IBAH has received all necessary consents
from holders of IBAH Warrants to effect the transactions contemplated by Section
2.8(c) hereof (together with the consent contemplated by the prior sentence, the
"Preferred and Warrant Consent"). IBAH has delivered to Omnicare a true and
complete copy of the Preferred and Warrant Consent. Each Transaction Document
executed and delivered by IBAH as of the date hereof has been duly executed and
delivered by IBAH and constitutes a valid and binding obligation of IBAH,
enforceable against IBAH in accordance with its terms. Any Transaction Document
executed and delivered by IBAH after the date hereof will be duly executed and
delivered by IBAH and will constitute a valid and binding obligation of IBAH,
enforceable against IBAH in accordance with its terms.
Section 4.3. Validity of Contemplated Transactions. Except for
-------------------------------------
compliance with (i) the HSR Act, (ii) the Securities Act and the Exchange Act
and (iii) the filing of the Certificate of Merger with the Secretary of State of
the State of Delaware and for any items specified in the IBAH Disclosure
---------------
Schedule (the "IBAH Required Consents"), neither the execution and delivery by
- --------
IBAH of the respective Transaction Documents to which it is or will be a party,
nor the performance of the Transactions to be performed by it, will require any
filing, consent or approval under or constitute a Default, or result in a loss
of material benefit under, (a) any Law or Court Order to which any IBAH Company
is subject, (b) the Charter Documents or bylaws of any IBAH Company, (c) any
customer Contract (other than letters of intent and agreements in principle) or
any other Contract involving an amount in excess of $2,500,000 to which any IBAH
Company is a party or by which any of the IBAH Assets may be subject or (d) any
other Contracts to which any IBAH Company is a party or by which any of the IBAH
Assets may be subject, except in the case of (b) and (d) for Defaults which
would not have a Material Adverse Effect.
Section 4.4. Capitalization and Stock Ownership. The total authorized
----------------------------------
capital stock of IBAH consists of (a) 50,000,000 shares of IBAH Common Stock,
and (b) 2,000,000 shares of Preferred Stock, par value $0.01 per share, of which
999,554 shares have been designated Series A Convertible Preferred Stock (the
"IBAH Convertible Preferred Stock"). Of such authorized capital stock, the only
issued and outstanding shares on the date hereof are 23,544,312 IBAH Common
Shares and 749,665 IBAH Preferred Shares. Except as listed in the IBAH
----
Disclosure Schedule, there are no existing options, warrants, calls, commitments
- -------------------
or other rights of any character (including conversion or preemptive rights)
relating to the acquisition of any issued or unissued capital stock or other
securities of IBAH. The IBAH Disclosure Schedule sets forth, as of the date
------------------------
hereof, as to each option or warrant, the holder, date of grant, exercise price
and number of shares subject thereto. All of the issued and outstanding IBAH
Shares are validly issued, fully paid and non-assessable. Following the
Effective Time, no options, warrants, calls, commitments or other rights of any
character (including conversion or preemptive rights) will entitle any Person to
acquire any securities of the Surviving Corporation or any subsidiary thereof,
except with respect to Wholly-Owned Subsidiaries of IBAH that have preemptive
rights.
15
<PAGE>
Section 4.5. Board Recommendation. By a vote of the directors present at
--------------------
a meeting of IBAH's Board of Directors (which meeting was duly called and held
and at which a quorum was present), the Board of Directors of IBAH unanimously
(a) approved and adopted this Agreement, including the Merger and the other
Transactions, and determined that the Merger is fair to the stockholders of
IBAH, and (b) resolved to recommend approval and adoption of this Agreement,
including the Merger and the other Transactions, by the stockholders of IBAH.
Smith Barney has delivered to IBAH's Board of Directors its opinion dated the
date of this Agreement to the effect that on such date the Merger Consideration
is fair to the holders of IBAH Common Shares from a financial point of view. A
complete and correct copy of such opinion has been delivered to Omnicare.
Section 4.6. Proxy Statement. None of the information supplied or to be
---------------
supplied by or on behalf of any IBAH Company specifically for inclusion or
incorporation by reference in the Registration Statement will (except to the
extent revised or superseded by amendments or supplements contemplated hereby),
at the time the Registration Statement becomes effective under the Securities
Act, contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not
misleading. None of the information supplied or to be supplied by or on behalf
of any IBAH Company specifically for inclusion or incorporation by reference in
the Proxy Statement will (except to the extent revised or superseded by
amendments or supplements contemplated hereby), at the date it (or any such
amendment or supplement) is mailed to the stockholders of IBAH and at the time
of the IBAH Stockholder Meeting, contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which
they are made, not misleading. The Registration Statement and the Proxy
Statement (except for information relating solely to any Omnicare Company) will
comply in all material respects with the requirements of the Securities Act and
the Exchange Act and the Regulations promulgated thereunder.
Section 4.7. IBAH Disclosure Documents; Financial Statements. IBAH has
-----------------------------------------------
filed all required forms, reports, statements, schedules and other documents
with the SEC since January 1, 1995, including its (a) Annual Reports on Form 10-
K for the fiscal years ended December 31, 1996 and 1997, (b) all proxy
statements relating to IBAH's meetings of stockholders (whether annual or
special) held since January 1, 1995, and (c) all other reports or registration
statements filed by IBAH with the SEC since January 1, 1995 (collectively, the
"IBAH Disclosure Documents"). Each of such IBAH Disclosure Documents, at the
time it was filed, complied in all material respects with all applicable
requirements of the Securities Act and the Exchange Act, and with the forms and
Regulations of the SEC promulgated thereunder, and did not contain at the time
filed any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they are made, not
misleading. The financial statements, including all related notes and
schedules, contained in the IBAH Disclosure Documents (or incorporated by
reference therein) fairly present the consolidated financial position of IBAH as
at the respective dates thereof and the consolidated results of operations and
cash flows of IBAH for the periods indicated in accordance with GAAP applied on
a consistent basis throughout the periods
16
<PAGE>
involved (except for changes in accounting principles disclosed in the notes
thereto) and subject in the case of interim financial statements to normal year-
end adjustments and the absence of notes. For purposes of this Agreement, the
balance sheet of IBAH as of December 31, 1997 is referred to as the "IBAH
Balance Sheet" and the date thereof is referred to as the "IBAH Balance Sheet
Date."
Section 4.8. Absence of Undisclosed Liabilities. None of the IBAH
----------------------------------
Companies has any Liabilities except (a) to the extent reflected in the IBAH
Balance Sheet, (b) those Liabilities described in this Agreement or set forth on
Section 4.8 of the IBAH Disclosure Schedule, (c) those Liabilities incurred in
------------------------
the ordinary course of business since the IBAH Balance Sheet Date which would
not have a Material Adverse Effect and (d) those Liabilities not required under
GAAP to be reflected in the IBAH Balance Sheet which would not have a Material
Adverse Effect.
Section 4.9. Taxes.
-----
(a) Definitions:
"Code" means the Internal Revenue Code of 1986, as amended. All
----
citations to provisions of the Code, or to the Treasury Regulations promulgated
thereunder, shall include any amendments thereto and any substitute or successor
provisions thereto.
"Taxes" means any and all federal, state, local and foreign taxes,
-----
assessments and other governmental charges, duties, impositions, levies and
liabilities, including, without limitation, taxes based upon or measured by
gross receipts, income, profits, sales, use and occupation, and value added, ad
valorem, transfer, gains, franchise, withholding, payroll, recapture,
employment, excise, unemployment, insurance, social security, business license,
occupation, business organization, stamp, environmental and property taxes,
together with all interest, penalties and additions imposed with respect to such
amounts. For purposes of this Agreement, "Taxes" also includes any obligations
under any agreements or arrangements with any Person with respect to the
liability for, or sharing of, Taxes (including pursuant to Treas. Reg. (S)
1.1502-6 or comparable provisions of state, local or foreign Tax Law) and
including any liability for Taxes as a transferee or successor, by Contract or
otherwise.
"Tax Return" means any report, return, election, notice, estimate,
----------
declaration, information statement and other forms and documents (including all
schedules, exhibits and other attachments thereto) relating to and filed or
required to be filed with a taxing authority in connection with any Taxes
(including, without limitation, estimated Taxes).
(b) Except as set forth in the IBAH Disclosure Schedule, IBAH and each
------------------------
of its Subsidiaries (i) have timely filed (or, in the case of Tax Returns not
yet due, will timely file) with the appropriate governmental agencies all
material Tax Returns required to be filed on or before the Effective Time and
all such Tax Returns filed were true, correct and complete in all material
respects, and (ii) have paid (or, in the case of Taxes not yet due, will pay),
all Taxes shown on such Tax Returns.
17
<PAGE>
(c) Except as set forth in the IBAH Disclosure Schedule, each IBAH
------------------------
Company has (i) timely paid or caused to be paid all material Taxes and all
Taxes shown on Tax Returns that are or were due, except to the extent that a
sufficient reserve for Taxes has been reflected on the IBAH Balance Sheet and
(ii) provided a sufficient reserve on the IBAH Balance Sheet for the payment of
all Taxes not yet due and payable.
(d) Except as set forth in the IBAH Disclosure Schedule, no deficiency
------------------------
in respect of any Taxes which has been assessed against an IBAH Company remains
unpaid, except for Taxes being contested in good faith, and IBAH has no
knowledge of any unassessed Tax deficiencies or of any audits or investigations
pending or threatened against an IBAH Company with respect to any Taxes.
(e) Except as set forth in the IBAH Disclosure Schedule, no IBAH
------------------------
Company has extended or waived the application of any applicable statute of
limitations of any jurisdiction regarding the assessment or collection of any
Tax or any Tax Return.
(f) Except as set forth in the IBAH Disclosure Schedule, there are no
------------------------
liens for Taxes upon any assets of any IBAH Company except for liens for current
Taxes not yet due.
(g) Except as set forth in the IBAH Disclosure Schedule, each IBAH
------------------------
Company has (i) complied with all material provisions of the Code relating to
the withholding and payment of Taxes and (ii) has timely made all deposits
required by applicable Law to be made with respect to employees' withholding and
other payroll, employment or other withholding or related Taxes.
(h) Except as set forth in the IBAH Disclosure Schedule, no IBAH
------------------------
Company is a party to any contract, agreement, plan or arrangement that,
individually or in the aggregate, or when taken together with any payment that
may be made under this Agreement or any agreements contemplated hereby, could
give rise to the payment of any "excess parachute payment" within the meaning of
Section 280G of the Code. IBAH is not, and has not been within the past five
years, a "United States real property holding corporation" within the meaning of
Section 897(c)(2) of the Code.
(i) Except as set forth in the IBAH Disclosure Schedule, no IBAH
------------------------
Company is a party to any agreement relating to the allocating or sharing of the
payment of, or liability for, Taxes for any period (or portion thereof).
(j) To IBAH's knowledge, except for the group of which IBAH is
presently the ultimate parent, no IBAH Company has ever been a member of an
affiliated group of corporations (within the meaning of Section 1504 of the
Code).
(k) No IBAH Company has distributed the stock of any corporation in a
transaction satisfying the requirements of Section 355 of the Code since April
16, 1997.
Section 4.10. Title to Assets and Related Matters. Each IBAH Company has
-----------------------------------
good and marketable title to its part of the IBAH Assets, free from any
Encumbrances except (a) those Encumbrances specified on Section 4.10 of the IBAH
----
Disclosure Schedule or any Encumbrance
- -------------------
18
<PAGE>
in favor of any IBAH Company, (b) items described in any notes to the
consolidated financial statements of IBAH contained in IBAH's Annual Report on
Form 10-K for the fiscal year ended December 31, 1997 (the "IBAH 10-K") included
in the IBAH Disclosure Documents, (c) minor matters that would not have a
Material Adverse Effect, (d) constitutional and statutory liens arising from the
obligation to pay for the provision of materials or services not yet in Default
and Taxes not yet due and (e) IBAH Assets transferred among the IBAH Companies.
Section 4.11. Real Property. Section 4.11 of the IBAH Disclosure Schedule
------------- ------------------------
describes all material real estate leased by any IBAH Company as of the date
hereof and used in the operation of the IBAH Business as well as any other
material real estate that is in the possession of or leased by any IBAH Company
(as tenant or landlord) as of the date hereof. As of the date hereof, none of
the IBAH Companies owns any real property.
Section 4.12. Subsidiaries. Except as set forth on Section 4.12 of the
------------
IBAH Disclosure Schedule and except for its subsidiaries set forth on exhibit
- ------------------------
21.1 of the IBAH 10-K, as of the date hereof none of the IBAH Companies owns,
directly or indirectly, any interest or investment (whether equity or debt) in
any corporation, partnership, limited liability company, business trust, joint
venture or other legal entity. IBAH (or another IBAH Company) owns all of the
issued and outstanding shares of capital stock of each IBAH Subsidiary, free and
clear of any Encumbrances, other than as set forth in Section 4.12 of the IBAH
----
Disclosure Schedule or Encumbrances in favor of any IBAH Company. Except with
- -------------------
respect to Wholly-Owned Subsidiaries of IBAH that have preemptive rights, there
are no existing options, warrants, calls, commitments or other rights of any
character (including conversion or preemptive rights) relating to the
acquisition or voting of any issued or unissued capital stock or other
securities of any IBAH Subsidiary. All of the shares of capital stock of each
IBAH Subsidiary are duly and validly authorized and issued, fully paid and non-
assessable.
Section 4.13. Legal Proceedings; Compliance with Law; Governmental Permits.
------------------------------------------------------------
(a) Except as set forth on Section 4.13 of the IBAH Disclosure
---------------
Schedule or in the IBAH 10-K, there is no Litigation that is pending or, to
- --------
IBAH's knowledge, threatened against any IBAH Company that would have a Material
Adverse Effect. IBAH is and has been in compliance with all applicable Laws,
except where the failure to be in compliance would not have a Material Adverse
Effect. There has been no Default under any Laws applicable to any IBAH
Company, including Environmental Laws, except for any Defaults that would not
have a Material Adverse Effect. There has been no Default with respect to any
Court Order applicable to any IBAH Company. Except as set forth on Section 4.13
of the IBAH Disclosure Schedule, no IBAH Company has received any written notice
------------------------
and, to the knowledge of any IBAH Company, no other communication has been
received to the effect that it is not in compliance with any applicable Laws,
and IBAH has no reason to believe that any presently existing circumstances are
likely to result in violations of any applicable Laws, except to the extent that
such failures to comply or violations would not have a Material Adverse Effect.
19
<PAGE>
(b) Without limiting the generality of Section 4.13(a), there is no
Environmental Condition at any property presently or formerly owned or leased by
an IBAH Company which is reasonably likely to have a Material Adverse Effect.
(c) The IBAH Companies have all material consents, permits,
franchises, licenses, concessions, registrations, certificates of occupancy,
approvals and other authorizations of Governmental Authorities (collectively,
the "Governmental Permits") required in connection with the operation of their
respective businesses as now being conducted, all of which are in full force and
effect, except where the failure to obtain any such Governmental Permit or of
any such Governmental Permit to be in full force and effect, would not have a
Material Adverse Effect. Each IBAH Company has complied, in all material
respects, with all of its Governmental Permits, except where the failure to so
comply would not have a Material Adverse Effect.
Section 4.14. Contracts and Commitments. Section 4.14 of the IBAH
------------------------- ----
Disclosure Schedule sets forth a complete and accurate list of:
- -------------------
(a) To IBAH's knowledge, customer Contracts (excluding letters of
intent and agreements in principle) involving any IBAH Company in amounts in
excess of $2,500,000; provided that the cumulative effect of all such Contracts
over $2.5 million not disclosed will not have a Material Adverse Effect.
(b) Other than Contracts listed as Exhibits to the IBAH 10-K, (i)
all employment, consulting (other than physician investigators), management,
severance or agency Contracts (y) with any executive officers or directors of
IBAH, or (z) allowing the other party to terminate and receive payment based on
the execution of this Agreement and consummation of the Transactions, and (ii)
any employment agreements with any Person in the United States to whom any IBAH
Company makes annual salary payments in excess of $150,000 and all employee
country managers outside the United States.
(c) All Contracts limiting the freedom of any IBAH Company to compete
in any line of business, or with any Person, or in any geographic area or
market.
Each Contract to which any IBAH Company is a party (i) is legal,
valid, binding and enforceable against IBAH or the applicable Subsidiary, and to
IBAH's knowledge, against each other party thereto, and is in full force and
effect and (ii) neither IBAH nor the applicable Subsidiary, nor to IBAH's
knowledge, any other party, is in Default under any such Contract, other than in
the case of (i) and (ii) above where the failure to be so would not have a
Material Adverse Effect.
Section 4.15. Employee Relations. No IBAH Company is (a) a party to,
------------------
involved in or, to IBAH's knowledge, threatened by, any labor dispute or unfair
labor practice charge, or (b) currently negotiating any collective bargaining
agreement, and no IBAH Company has experienced any work stoppage during the last
three years.
Section 4.16. ERISA.
-----
20
<PAGE>
(a) The IBAH Disclosure Schedule contains a complete list of all
------------------------
Benefit Plans sponsored or maintained by any IBAH Company or under which any
IBAH Company may be obligated for its employees, directors or independent
contractors ("IBAH Benefit Plans"). IBAH has delivered or made available to
Omnicare (i) accurate and complete copies of all IBAH Benefit Plan documents and
of any summary plan descriptions, summary annual reports and insurance contracts
relating thereto, (ii) accurate and complete detailed summaries of all unwritten
IBAH Benefit Plans, (iii) accurate and complete copies of the most recent
financial statements and actuarial reports with respect to all IBAH Benefit
Plans for which financial statements or actuarial reports are required or have
been prepared and (iv) accurate and complete copies of all annual reports for
all IBAH Benefit Plans (for which annual reports are required) prepared within
the last two years.
(b) All IBAH Benefit Plans conform in all material respects to, and
are being administered and operated in material compliance with, the
requirements of ERISA, the Code and all other applicable Laws, including
applicable Laws of foreign jurisdictions. There have not been any "prohibited
transactions," as such term is defined in Section 4975 of the Code or Section
406 of ERISA involving any of the IBAH Benefit Plans, that could subject any
IBAH Company to any material penalty or tax imposed under the Code or ERISA.
(c) Except as set forth on Section 4.16(c) of the IBAH Disclosure
---------------
Schedule, any IBAH Benefit Plan that is intended to be qualified under Section
- --------
401(a) of the Code and exempt from tax under Section 501(a) of the Code has been
determined by the Internal Revenue Service to be so qualified, and such
determination remains in effect and has not been revoked. Nothing has occurred
since the date of any such determination that is reasonably likely to affect
adversely such qualification or exemption, or result in the imposition of excise
taxes or income taxes on unrelated business income under the Code or ERISA with
respect to any IBAH Benefit Plan.
(d) Except as set forth on Section 4.16(d) of the IBAH Disclosure
---------------
Schedule, (i) no IBAH Company has a current or contingent obligation to
- --------
contribute to any multiemployer plan (as defined in Section 3(37) of ERISA) and
(ii) no IBAH Company, nor any entity that has been treated as a single employer
with any IBAH Company under Sections 414(b), (c), (m) or (o) of the Code, has
any liability, contingent or otherwise, under Title IV of ERISA or Section 412
of the Code.
(e) There are no pending or, to the knowledge of IBAH, threatened
claims by or on behalf of any IBAH Benefit Plans, or by or on behalf of any
individual participants or beneficiaries of any IBAH Benefit Plans, alleging any
breach of fiduciary duty on the part of any IBAH Company or any of the officers,
directors or employees of any IBAH Company under ERISA or any other applicable
Regulations, or claiming benefit payments other than those made in the ordinary
operation of such plans, or alleging any violation of any other applicable Laws.
To IBAH's knowledge, the IBAH Benefit Plans are not the subject of any
investigation, audit or action by the Internal Revenue Service, the Department
of Labor or the Pension Benefit Guaranty Corporation ("PBGC"). Each IBAH
Company has made all required contributions under the
21
<PAGE>
IBAH Benefit Plans including the payment of any premiums payable to the PBGC and
other insurance premiums.
(f) With respect to any IBAH Benefit Plan that is an employee welfare
benefit plan (within the meaning of Section 3(1) of ERISA) (an "IBAH Welfare
Plan"), (i) each IBAH Welfare Plan for which contributions are claimed as
deductions under any provision of the Code is in material compliance with all
applicable requirements pertaining to such deduction, (ii) with respect to any
welfare benefit fund (within the meaning of Section 419 of the Code) related to
an IBAH Welfare Plan, there is no disqualified benefit (within the meaning of
Section 4976(b) of the Code) that would result in the imposition of a tax under
Section 4976(a) of the Code, and (iii) any IBAH Benefit Plan that is a group
health plan (within the meaning of Section 4980B(g)(2) of the Code) complies,
and in each and every case has complied, with all of the material requirements
of Section 4980B of the Code, ERISA, Title XXII of the Public Health Service Act
and the applicable provisions of the Social Security Act.
(g) Except as set forth on the IBAH Disclosure Schedule or for any
------------------------
IBAH Benefit Plan listed as an exhibit to the IBAH 10-K, the execution of this
Agreement and the performance of the Transactions will not (either alone or in
combination with the occurrence of any additional or subsequent events)
constitute an event under any IBAH Benefit Plan that will or may result in any
payment (whether of severance pay or otherwise), acceleration, forgiveness of
indebtedness, vesting, distribution, increase in benefits or obligation to fund
benefits with respect to any current or former employee, director or consultant
of any IBAH Company.
Section 4.17. Patents, Trademarks, etc. None of the IBAH Companies uses in
-------------------------
the operation of the IBAH Business any material registered Patents, Trademarks
or Copyrights, except for those described in Section 4.17 of the IBAH Disclosure
---------------
Schedule or Trademarks which are names of IBAH Companies. To IBAH's knowledge,
- --------
no IBAH Company infringes upon or unlawfully or wrongfully uses any Intellectual
Property (other than computer software) owned or claimed by another Person and
no Person infringes on or wrongfully uses any Intellectual Property (other than
computer software) owned or claimed by IBAH, except for those situations that
would not have a Material Adverse Effect. The IBAH Companies own or have valid
rights to use all Intellectual Property used in the conduct of their business
except where the failure to have valid rights to use such Intellectual Property
will not have a Material Adverse Effect, free and clear of all Encumbrances,
other than Encumbrances which would not have a Material Adverse Effect.
Section 4.18. Absence of Certain Changes. Since the IBAH Balance Sheet
--------------------------
Date, the IBAH Companies have conducted the IBAH Business in the ordinary
course, and except as described in the IBAH Disclosure Schedule, as of the date
------------------------
hereof, there has not been:
(a) any Material Adverse Effect on the IBAH Business or in the
aggregate Liabilities of the IBAH Companies;
22
<PAGE>
(b) any distribution or payment declared or made in respect of IBAH's
capital stock by way of dividends, purchase or redemption of shares or
otherwise, except redemptions pursuant to the IBAH Employee Stock Purchase Plan
pursuant to the terms thereof;
(c) any increase in the compensation payable or to become payable to
any current director, officer or employee of any IBAH Company, except for merit
and seniority increases for employees made in the ordinary course of business,
nor any material change in any existing employment, severance, consulting
arrangements or any IBAH Benefit Plan;
(d) any sale, assignment or transfer of any IBAH Assets, or any
additions to or transactions involving any IBAH Assets, other than those made in
the ordinary course of business or those solely involving the IBAH Companies;
(e) other than in the ordinary course of business, any waiver or
release of any material claim or right or cancellation of any material debt held
by any IBAH Company;
(f) any change in practice with respect to Taxes, or any election,
change of any election, or revocation of any election with respect to Taxes, or
any settlement or compromise of any dispute involving a Tax liability;
(g) (i) any creation, assumption or maintenance of any long-term debt
or any short-term debt for borrowed money other than under existing notes
payable, lines of credit or other credit facility or in the ordinary course of
business or with respect to its Wholly-Owned Subsidiaries; (ii) any assumption,
granting of guarantees, endorsements or otherwise becoming liable or responsible
(whether directly, contingently or otherwise) for the obligations of any other
Person except its Wholly-Owned Subsidiaries; or (iii) any loans, advances or
capital contributions to, or investments in, any other Person except its Wholly-
Owned Subsidiaries;
(h) any material agreement, commitment or contract, except
agreements, commitments or contracts for the purchase, sale or lease of goods or
services in the ordinary course of business;
(i) other than in the ordinary course of business, any authorization,
recommendation, proposal or announcement of an intention to authorize, recommend
or propose, or enter into any Contract with respect to, any (i) plan of
liquidation or dissolution, (ii) acquisition of a material amount of assets or
securities, (iii) disposition or Encumbrance of a material amount of assets or
securities, (iv) merger or consolidation or (v) material change in its
capitalization;
(j) any change in accounting or Tax procedure or practice; or
(k) any compromise, settlement or modification to any material claim
or litigation.
23
<PAGE>
Section 4.19. Corporate Records. The minute books of IBAH contain
-----------------
accurate, complete and current copies of all Charter Documents and of all
minutes of meetings, resolutions and other proceedings of its Board of Directors
and stockholders. The stock record books of IBAH are also complete, correct and
current.
Section 4.20. Finder's Fees. Except for Smith Barney, the arrangements
-------------
with which have been disclosed to Omnicare, no Person is or will be entitled to
any commission, finder's or other payment in connection with the Transactions
based on arrangements made by or on behalf of IBAH. A true and complete copy of
each document reflecting such arrangements with Smith Barney has been delivered
to Omnicare.
Section 4.21. Compliance with Healthcare Laws.
-------------------------------
(a) As used herein, "IBAH Healthcare Laws" shall mean any Laws to
which any IBAH Company is subject with respect to drug or medical device
investigation or development regulation or other applicable healthcare
regulatory matters, including, without limitation, the Federal Food, Drug and
Cosmetic Act, 21 U.S.C. (S)301 et seq.; the Controlled Substances Act, 21 U.S.C.
(S)801 et seq.; 18 U.S.C. (S)287 (commonly referred to as the "Civil False
Claims Act"), and implementing regulations related thereto. To IBAH's knowledge,
there are no presently existing circumstances which could be reasonably likely
to result in violations of any such IBAH Healthcare Laws, except where such
violations would not have a Material Adverse Effect. To the knowledge of IBAH,
no IBAH Company has been materially sanctioned as not being in compliance with
any IBAH Healthcare Laws except where such sanctions would not have a Material
Adverse Effect. No IBAH Company has received any written notice and, to the
knowledge of any IBAH Company, no other communication has been received to the
effect that it or any activity conducted by it is not in compliance with any
applicable IBAH Healthcare Laws except where the failure to comply would not
have a Material Adverse Effect. As used herein, "IBAH Personnel" shall mean the
respective officers, directors and employees of the IBAH Companies.
(b) No IBAH Company receives or to IBAH's knowledge has received
payment either directly or indirectly from Medicare, Medicaid, the Civilian
Health and Medical Program of the Uniformed Services or the Federal Employees
Health Benefits Act.
(c) No IBAH Company has made, and, to the knowledge of any IBAH
Company, no IBAH Personnel have made, directly or indirectly, any bribes,
kickbacks, or other illegal payments or illegal political contributions, illegal
payments from corporate funds to governmental officials in their individual
capacities, or illegal payments from corporate funds to obtain or retain
business either within the United States or abroad.
(d) No IBAH Company nor, to IBAH's knowledge, any of their IBAH
Personnel have been debarred by the U.S. Food and Drug Administration (the
"FDA") or by an analogous foreign governmental entity pursuant to the Generic
Drug Enforcement Act ("Drug Enforcement Act") or an analogous foreign law or
regulation; and to IBAH's knowledge, no IBAH Company or any of its IBAH
Personnel are under investigation by the FDA or by an analogous foreign
24
<PAGE>
governmental entity for a debarment action pursuant to the Drug Enforcement Act
or an analogous foreign law or regulation.
(e) No IBAH Personnel of any IBAH Company are engaged as practicing
physicians, nurses or pharmacists (billing patients for professional services
directly and not through any IBAH Company) on behalf of any IBAH Company.
Section 4.22. Board Approval. The IBAH Board of Directors has approved
--------------
this Agreement and the Transactions and such approval constitutes approval of
the Merger and the other Transactions contemplated hereby, including approval of
the Voting Agreement, the Stock Option Agreement and the other Transaction
Documents, by the IBAH Board of Directors as contemplated by the DGCL.
Section 4.23. Pooling of Interests; Reorganization. No IBAH Company has
------------------------------------
or, as of the Closing Date, will have (a) taken any action or failed to take any
action which action or failure would jeopardize the treatment of the Merger as a
pooling of interests for accounting purposes or (b) taken any action or failed
to take any action which action or failure would result in the failure of the
Merger to qualify as a reorganization within the meaning of Code Section 368(a).
IBAH has no knowledge of any fact or circumstance that is reasonably likely to
prevent the Merger from qualifying as a pooling of interests for accounting
purposes or a reorganization within the meaning of Code Section 368(a).
Section 4.24. Insurance. IBAH carries insurance covering it and its
---------
Subsidiaries' assets, business, operations, employees, officers and directors of
the type and in the amounts listed in Section 4.24 of the IBAH Disclosure
---------------
Schedules. All such insurance policies are in full force and effect and all
- ---------
premiums have been paid to the extent they are due. To IBAH's knowledge, no
claims have been made by any Person alleging liability in respect of drug trials
on human beings by any IBAH Company.
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF OMNICARE
Omnicare hereby represents and warrants to IBAH as follows:
Section 5.1. Corporate. Each Omnicare Company is a corporation duly
---------
organized, validly existing and in good standing under the Laws under which it
was incorporated. Each Omnicare Company is qualified to do business as a
foreign corporation in any jurisdiction where it is required to be so qualified,
except where the failure to so qualify would not have a Material Adverse Effect.
The Charter Documents and bylaws of Omnicare (which have been delivered to IBAH)
and of each Omnicare Company (which have been delivered or made available upon
request to IBAH) have been duly adopted and are current, correct and complete.
Each Omnicare Company has all necessary corporate power and authority to own,
lease and operate its part of the Omnicare Assets and to carry on its part of
the Omnicare Business as it is now being conducted.
25
<PAGE>
Section 5.2. Authorization. Each Omnicare Party has the requisite
-------------
corporate power and authority to execute and deliver the Transaction Documents
to which it is a party and to perform the Transactions to be performed by it.
Such execution, delivery and performance by each Omnicare Party have been duly
authorized by all necessary corporate action. Each Transaction Document
executed and delivered by any Omnicare Party as of the date hereof has been duly
executed and delivered by such Omnicare Party and constitutes a valid and
binding obligation of each Omnicare Party, enforceable against each Omnicare
Party in accordance with its terms. Any Transaction Document executed and
delivered by any Omnicare Party after the date hereof will be duly executed and
delivered by such Omnicare Party and will constitute a valid and binding
obligation of such Omnicare Party, enforceable against such Omnicare Party in
accordance with its terms.
Section 5.3. Validity of Contemplated Transactions. Except for
-------------------------------------
compliance with the (i) HSR Act, (ii) the Securities Act and the Exchange Act
and (iii) the filing of the Certificate of Merger with the Secretary of State of
the State of Delaware, neither the execution and delivery by any Omnicare Party
of the respective Transaction Documents to which it is or will be a party, nor
the performance of the Transactions to be performed by it, will require any
filing, consent or approval under or constitute a Default, or result in a loss
of material benefit under, (a) any Law or Court Order to which any Omnicare
Company is subject, (b) the Charter Documents or bylaws of any Omnicare Company
or (c) any Contract or other document to which any Omnicare Company is a party
or by which any of the Omnicare Assets may be subject, except in the case of (b)
and (c) for Defaults which would not have a Material Adverse Effect.
Section 5.4. Capitalization and Stock Ownership. The total authorized
----------------------------------
capital stock of Omnicare consists of (a) 110,000,000 shares of Omnicare Common
Stock, and (b) 1,000,000 shares of Omnicare preferred stock, no par value. Of
such authorized capital stock, the only issued and outstanding shares as of
March 27, 1998 are 82,730,691 shares of Omnicare Common Stock. As of March 27,
1998, there are no existing options, warrants, calls, commitments or other
rights of any character (including conversion or preemptive rights) relating to
the acquisition of any issued or unissued capital stock or other securities of
Omnicare, other than options, warrants and other rights to purchase an aggregate
of 11,628,603 shares of Omnicare Common Stock. All of the issued and
outstanding Omnicare Shares are validly issued, fully paid and non-assessable.
The total authorized capital stock of the Merger Subsidiary consists of 1,000
shares of common stock, par value $.01 per share (the "Omnicare Sub Common
Stock"). Of such authorized capital stock, the only issued and outstanding
shares on the date hereof are held by Omnicare. All of the issued and
outstanding shares of Omnicare Sub Common Stock are validly issued, fully paid
and non-assessable. The shares of Omnicare Common Stock to be issued in
connection with the Merger and this Agreement, when issued in accordance with
the terms of this Agreement, will be validly issued, fully paid and
nonassessable.
Section 5.5. Board Recommendation. By a vote of the directors present at
--------------------
a meeting of Omnicare's Board of Directors (which meeting was duly called and
held and at which a quorum was present), the Board of Directors of Omnicare
unanimously approved and adopted this
26
<PAGE>
Agreement, including the Merger and the other Transactions, and determined that
the Merger is fair to Omnicare.
Section 5.6. Proxy Statement. None of the information supplied or to be
---------------
supplied by or on behalf of any Omnicare Company specifically for inclusion or
incorporation by reference in the Registration Statement will (except to the
extent revised or superseded by amendments or supplements contemplated hereby),
at the time the Registration Statement becomes effective under the Securities
Act, contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not
misleading. None of the information supplied or to be supplied by or on behalf
of any Omnicare Company specifically for inclusion or incorporation by reference
in the Proxy Statement will (except to the extent revised or superseded by
amendments or supplements contemplated hereby), at the date it (or any such
amendment of supplement) is mailed to the stockholders of IBAH and at the time
of the IBAH Stockholder Meeting, contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which
they are made, not misleading. The Registration Statement and the Proxy
Statement (except for information relating solely to any IBAH Company) will
comply in all material respects with the requirements of the Securities Act and
the Exchange Act and the Regulations promulgated thereunder.
Section 5.7. Omnicare Disclosure Documents; Financial Statements.
---------------------------------------------------
Omnicare has filed all required forms, reports, statements, schedules and other
documents with the SEC since January 1, 1995 (collectively, the "Omnicare
Disclosure Documents"). Each of such Omnicare Disclosure Documents, at the time
it was filed, complied in all material respects with all applicable requirements
of the Securities Act and the Exchange Act, and with the forms and Regulations
of the SEC promulgated thereunder, and did not contain at the time filed any
untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they are made, not misleading. The
financial statements, including all related notes and schedules, contained in
the Omnicare Disclosure Documents (or incorporated by reference therein) fairly
present the consolidated financial position of Omnicare as at the respective
dates thereof and the consolidated results of operations and cash flows of
Omnicare for the periods indicated in accordance with GAAP applied on a
consistent basis throughout the periods involved (except for changes in
accounting principles disclosed in the notes thereto) and subject in the case of
interim financial statements to normal year-end adjustments and the absence of
notes. For purposes of this Agreement, the balance sheet of Omnicare as of
December 31, 1997 is referred to as the "Omnicare Balance Sheet" and the date
thereof is referred to as the "Omnicare Balance Sheet Date."
Section 5.8. Absence of Undisclosed Liabilities. None of the Omnicare
----------------------------------
Companies has any Liabilities except (a) to the extent reflected in the Omnicare
Balance Sheet, (b) those Liabilities described in this Agreement, (c) those
Liabilities incurred in the ordinary course of business since the Omnicare
Balance Sheet Date which would not have a Material Adverse
27
<PAGE>
Effect and (d) those Liabilities not required under GAAP to be reflected in the
Omnicare Balance Sheet which would not have a Material Adverse Effect.
Section 5.9. Absence of Certain Changes. Since the Omnicare Balance Sheet
--------------------------
Date, there has not been any Material Adverse Effect on the Omnicare Business.
Section 5.10. Pooling of Interests; Reorganization. No Omnicare Company
------------------------------------
has or, as of the Closing Date, will have (a) taken any action or failed to take
any action which action or failure would jeopardize the treatment of the Merger
as a pooling of interests for accounting purposes or (b) taken any action or
failed to take any action which action or failure would result in the failure of
the Merger to qualify as a reorganization within the meaning of Code Section
368(a). Omnicare has no knowledge of any fact or circumstance that is reasonably
likely to prevent the Merger from qualifying as a pooling of interests for
accounting purposes or a reorganization within the meaning of Code Section
368(a).
Section 5.11. Ownership of Merger Subsidiary; No prior Activities. The
---------------------------------------------------
Merger Subsidiary is a Wholly-Owned Subsidiary of Omnicare created solely for
the purpose of effecting the Merger. As of the date hereof and the Effective
Time, except for Liabilities incurred in connection with its incorporation or
organization and the Transactions and except for this Agreement and the other
Transaction Documents, the Merger Subsidiary has not and will not have incurred,
directly or indirectly, through any Subsidiary or Affiliate of Omnicare, any
material Liabilities, engaged in any material business activities of any type or
kind whatsoever or entered into any agreements or arrangements with any Person.
Section 5.12. Compliance With Healthcare Laws.
-------------------------------
(a) As used herein, "Omnicare Healthcare Laws" shall mean any Laws to
which any Omnicare Company is subject with respect to drug or medical device
investigation or development regulation or other applicable healthcare
regulatory matters, including, without limitation, the Controlled Substances
Act, 21 U.S.C. (S)801 et seq.; 18 U.S.C. (S)287 (commonly referred to as the
"Civil False Claims Act"); (S)1128Bb(b) of the Social Security Act and 42 U.S.C.
(S) 1320a-7b(b) (commonly referred to as the "Federal Anti-Kickback Statute");
(S)1877 of the Social Security Act and 42 U.S.C. (S)1395nn (commonly referred to
as the "Stark Statute"); the Animal Welfare Act, 7 U.S.C. (S)2131 et. seq., and
implementing regulations related thereto. To Omnicare's knowledge, there are no
presently existing circumstances which could be reasonably likely to result in
violations of any such Omnicare Healthcare Laws, except where such violations
would not have a Material Adverse Effect. To the knowledge of Omnicare, no
Omnicare Company has been sanctioned as not being in compliance with any
Omnicare Healthcare Laws except where such sanctions would not have a Material
Adverse Effect. Except as disclosed in Omnicare's Annual Report on Form 10-K for
the year ended December 31, 1997, no Omnicare Company has received any written
notice and, to the knowledge of any Omnicare Company, no other communication has
been received to the effect that it or any activity conducted by it is not in
compliance with any applicable Omnicare Healthcare Laws except where the failure
to comply would not have a Material Adverse Effect.
28
<PAGE>
(b) Except as disclosed in Omnicare's Annual Report on Form 10-K for
the year ended December 31, 1997, to Omnicare's knowledge, no Omnicare Company
is presently the subject of an investigation by a Governmental Authority for a
violation of any applicable Omnicare Healthcare Laws, except for such violations
that would not have a Material Adverse Effect.
ARTICLE VI
COVENANTS OF THE OMNICARE PARTIES AND IBAH
Section 6.1. Proxy/Registration Statement. Omnicare and IBAH will prepare
----------------------------
and file with the SEC as soon as reasonably practicable after the date hereof a
proxy statement to be filed under the Exchange Act by IBAH and to be distributed
by IBAH in connection with the IBAH Stockholder Meeting (the "Proxy Statement"
and, together with the Registration Statement, the "Proxy/Registration
Statement"). Such filing will be a confidential filing unless Omnicare shall
specify otherwise. No later than promptly following the clearance by the SEC of
the Proxy Statement, Omnicare will file a Registration Statement on Form S-4
under the Securities Act in connection with the Merger for purposes of
registering the Omnicare Shares and the Omnicare Warrants (and the shares of
Omnicare Common Stock issuable upon exercise of the Omnicare Warrants) to be
issued in the Merger pursuant to Article II hereof (the "Registration
Statement") and IBAH shall cooperate with Omnicare to cause the Registration
Statement to be declared effective under the Securities Act as promptly as
practicable after such filing. Omnicare and IBAH shall also take such action as
may be reasonably required to cause the Omnicare Shares and the Omnicare
Warrants issuable pursuant to the Merger (and the shares of Omnicare Common
Stock issuable upon exercise of the Omnicare Warrants) to be registered or to
obtain an exemption from registration under applicable state "blue sky" or
securities Laws. Each Party will furnish to the other Party all information
concerning itself and its Subsidiaries as the other Party or its counsel may
reasonably request and that is required or customary for inclusion in the
Proxy/Registration Statement.
Section 6.2. HSR Act Filings. Each Party shall prepare and cause to be
---------------
filed with appropriate governmental authorities, as soon as reasonably
practicable after the date hereof, any required Notification and Report Form for
Certain Mergers and Acquisitions or responses thereto as required by the HSR Act
and any necessary supplements and amendments thereto. Each Party shall use
commercially reasonably efforts to cooperate in promptly preparing and filing
such Notification and Report Form and seeking the prompt expiration of the
applicable waiting period.
Section 6.3. No Solicitation. From and after the date hereof, IBAH,
---------------
without the prior written consent of Omnicare, will not, and will not authorize
or permit any of its Subsidiaries or its Party Representatives to, directly or
indirectly, solicit, initiate or encourage (including by way of furnishing
information) or take any other action to facilitate knowingly any inquiries or
the making of any proposal which constitutes or may reasonably be expected to
lead to an Acquisition Proposal (as defined below) from any Person, or engage in
any discussion or negotiations relating thereto or accept any Acquisition
Proposal; provided, however, that
29
<PAGE>
notwithstanding any other provision hereof, IBAH may (a) at any time prior to
the time IBAH's stockholders shall have voted to approve this Agreement, engage
in discussions or negotiations with a third party who (without any solicitation,
initiation, encouragement, discussion or negotiation, directly or indirectly, by
or with any IBAH Company or its Party Representatives after the date hereof)
seeks to initiate such discussions or negotiations and may furnish such third
party information concerning IBAH and its Business and Assets if, and only to
the extent that, (i)(x) the third party has first made an Acquisition Proposal
that is (as determined in good faith by the IBAH Board of Directors after
consultation with its financial advisor) financially superior to the
Transactions and has demonstrated that the funds necessary for the Acquisition
Proposal are reasonably likely to be available and the Acquisition Proposal is
reasonably capable of consummation in accordance with its terms (as determined
in good faith in each case by IBAH's Board of Directors after consultation with
its financial advisors) and (y) IBAH's Board of Directors shall conclude in good
faith, after considering applicable provisions of applicable Law, on the basis
of advice of its counsel, that such action is necessary for the Board of
Directors to act in a manner consistent with its fiduciary duties under
applicable Law and (ii) prior to furnishing such information to or entering into
discussions or negotiations with such Person, IBAH (x) provides prompt notice to
Omnicare to the effect that it is furnishing information to or entering into
discussions or negotiations with such Person and (y) receives from such Person
an executed confidentiality agreement in reasonably customary form on terms not
in the aggregate materially more favorable to such Person than the terms
contained in the Confidentiality Agreement, (b) comply with Rule 14e-2
promulgated under the Exchange Act with regard to a tender or exchange offer,
and/or (c) provided IBAH terminates this Agreement pursuant to Section 12.1(g),
accept an Acquisition Proposal from a third party. IBAH shall immediately cease
and terminate any existing solicitation, initiation, encouragement, activity,
discussion or negotiation with any Persons conducted heretofore by IBAH or its
Party Representatives with respect to the foregoing. IBAH shall not release any
third party from, or waive any provision of, any standstill agreement to which
it is a party or any confidentiality agreement between it and another Person who
has made an Acquisition Proposal, unless such Person has made an Acquisition
Proposal meeting the criteria set forth in clause (a)(i)(x) above and IBAH's
Board of Directors shall conclude in good faith, after considering applicable
provisions of applicable Law, on the basis of advice of its counsel, that such
action is necessary for the Board of Directors to act in a manner consistent
with its fiduciary duties under applicable Law. IBAH shall immediately notify
Omnicare orally (with a prompt written confirmation) of any such inquiries,
offers or proposals (including the terms and conditions of any such proposal and
the identity of the Person making it and shall provide copies of any such
written inquiries, offers or proposals), shall keep Omnicare informed of the
status and details of any such inquiry, offer or proposal (and agrees that any
material modification of the terms of an inquiry or proposal shall constitute a
new inquiry or proposal) , and shall give Omnicare five days' advance notice of
any agreement to be entered into with, or any information to be supplied to, any
Person making such inquiry, offer or proposal (no such agreement, other than a
confidentiality agreement as set forth in this Section, to be executed or agreed
prior to the termination of this Agreement in accordance with its terms). As
used herein, "Acquisition Proposal" shall mean a bona fide proposal or offer
(other than by Omnicare) for a tender or exchange offer, merger, consolidation
or other business combination involving IBAH or any Subsidiary thereof, or any
proposal to acquire in any manner a substantial equity interest in, or a
substantial amount of the assets of, IBAH or any such Subsidiary.
30
<PAGE>
Section 6.4. Notification of Certain Matters. Each of Omnicare and IBAH
-------------------------------
shall give prompt notice to the other of the following:
(a) the occurrence or nonoccurrence of any event whose occurrence or
nonoccurrence would be likely to cause either (i) any representation or warranty
contained in this Agreement to be untrue or inaccurate in any material respect
at any time from the date hereof to the Effective Time, or (ii) directly or
indirectly, any Material Adverse Effect;
(b) any material failure of such Party, or any officer, director,
employee or agent of any thereof, to comply with or satisfy any covenant,
condition or agreement to be complied with or satisfied by it hereunder; and
(c) any facts relating to such Party which would make it necessary or
advisable to amend the Proxy Statement or the Registration Statement in order to
make the statements therein not misleading or to comply with applicable Law;
provided, however, that the delivery of any notice pursuant to this Section 6.4
shall not limit or otherwise affect the remedies available hereunder to the
Party receiving such notice.
Section 6.5. Access to Information.
---------------------
(a) From the date hereof to the Effective Time, Omnicare and IBAH
shall, and shall cause its respective Subsidiaries, and its and their officers,
directors, employees, auditors, counsel and agents to afford the officers,
employees, auditors, counsel, financial advisors and agents of the other Party
complete access at all reasonable times to such Party's and its Subsidiaries'
officers, employees, auditors, counsel, agents, properties, offices and other
facilities and to all of their respective books and records, and shall furnish
the other with all financial, operating and other data and information as such
other Party may reasonably request.
(b) All information so received from the other Party shall be deemed
received pursuant to the confidentiality agreement, dated as of December 17,
1997, heretofore executed and delivered by Omnicare and IBAH (the
"Confidentiality Agreement"), and each such Party shall, and shall cause its
Subsidiaries and each of its and their respective officers, directors,
employees, auditors, counsel, financial advisors and agents ("Party
Representatives"), to comply with the provisions of the Confidentiality
Agreement with respect to such information. The provisions of the
Confidentiality Agreement are hereby incorporated herein by reference with the
same effect as if fully set forth herein.
Section 6.6. Public Announcements. Omnicare and IBAH (a) shall use all
--------------------
reasonable efforts to develop a joint communications plan and each Party shall
use all reasonable efforts to ensure that all press releases and other public
statements with respect to the Transactions shall be consistent with such joint
communications plan or, to the extent inconsistent therewith, shall have
received the prior written approval of the other and (b) before issuing any
press release or otherwise making any public statements with respect to the
Transactions, will consult with each other as to its form and substance and
shall not issue any such press release or make any such
31
<PAGE>
public statement prior to such consultation, except for each of (a) and (b)
above as may be required by Law (it being agreed that the Parties hereto are
entitled to disclose all requisite information concerning the Transactions in
any filings required with the SEC or pursuant to the HSR Act) or the rules and
regulations of the Nasdaq National Market promulgated by the National
Association of Securities Dealers, Inc. or the NYSE, as applicable.
Section 6.7. Cooperation. Upon the terms and subject to the conditions
-----------
hereof, each of the Parties shall use its commercially reasonable efforts to
take or cause to be taken all actions and to do or cause to be done all things
necessary, proper or advisable to consummate as promptly as practicable the
Transactions and shall use its commercially reasonable efforts to obtain all
IBAH Required Consents, and to effect all necessary filings, under the
Securities Act, the Exchange Act and the HSR Act. Without limiting the
generality of the foregoing, each Party shall use all commercially reasonable
efforts to take, or cause to be taken, all other actions and to do, or cause to
be done, all other things necessary, proper or advisable to fulfill the
conditions under Articles IX, X and XI to the extent that the fulfillment
thereof is within a Party's control.
Section 6.8. Reorganization; Pooling. From and after the date hereof and
-----------------------
until the Effective Time, neither Omnicare nor IBAH nor any of their respective
Subsidiaries shall knowingly take any action, or knowingly fail to take any
action, that would jeopardize qualification of the Merger as a reorganization
within the meaning of Section 368(a) of the Code or as a pooling of interests
under applicable accounting standards.
ARTICLE VII
COVENANTS OF IBAH
Section 7.1. Operation of the Business. Except as set forth on Section
-------------------------
7.1 of the IBAH Disclosure Schedule, as contemplated by this Agreement or as
------------------------
expressly agreed to in writing by Omnicare, during the period from the date of
this Agreement to the Effective Time, IBAH and its Subsidiaries will conduct
their operations only in the ordinary course of business consistent with sound
financial, operational and regulatory practice (as used in Section 4.18 and 7.1,
the "ordinary course of business"), and will take no action which would
materially adversely affect their ability to consummate the Transactions.
Without limiting the generality of the foregoing, except as otherwise expressly
provided in this Agreement or except as disclosed in the IBAH Disclosure
---------------
Schedule, prior to the Effective Time, neither IBAH nor any of its Subsidiaries
- --------
will, without the prior written consent of Omnicare:
(a) amend its Charter Documents or bylaws (or similar organizational
documents);
(b) authorize for issuance, issue, sell, deliver, grant any options
for, or otherwise agree or commit to issue, sell or deliver any shares of its
capital stock or any other securities, other than pursuant to and in accordance
with the terms of the IBAH Employee Stock Purchase Plan in the ordinary course
of business, the Stock Option Agreement, any Existing Options, or outstanding
IBAH Preferred Shares or IBAH Warrants listed on the IBAH Disclosure Schedule;
------------------------
32
<PAGE>
(c) recapitalize, split, combine or reclassify any shares of its
capital stock; declare, set aside or pay any dividend or other distribution
(whether in cash, stock or property or any combination thereof) in respect of
its capital stock; or purchase, redeem or otherwise acquire any of its or its
Subsidiaries' securities or modify any of the terms of any such securities;
(d) (i) create, incur, assume, maintain or permit to exist any long-
term debt or any short-term debt for borrowed money other than under existing
notes payable, lines of credit or other credit facilities or in the ordinary
course of business, or with respect to its Wholly-Owned Subsidiaries in the
ordinary course of business; (ii) assume, guarantee, endorse or otherwise become
liable or responsible (whether directly, contingently or otherwise) for the
obligations of any other Person except its Wholly-Owned Subsidiaries in the
ordinary course of business or as otherwise may be contractually required and
disclosed in the IBAH Disclosure Schedule; or
------------------------
(iii) make any loans, advances or capital contributions to, or investments in,
any other Person except its Wholly-Owned Subsidiaries;
(e) (i) amend any IBAH Benefit Plan or (ii) except in the ordinary
course of business consistent with usual practice or established policy (a)
increase in any manner the rate of compensation of any of its directors,
officers or other employees everywhere, except for increases that do not exceed
15% of the base salary or in the ordinary course of business; (b) pay or agree
to pay any bonus, pension, retirement allowance, severance or other employee
benefit except as required under currently existing IBAH Benefit Plans disclosed
in the IBAH Disclosure Schedule; or (c) amend, terminate or enter into any
------------------------
employment, consulting, severance, change in control or similar agreements or
arrangements with any of its directors, officers or other employees;
(f) enter into any material agreement, commitment or contract, except
agreements, commitments or contracts for the purchase, sale or lease of goods or
services in the ordinary course of business;
(g) other than in the ordinary course of business, authorize,
recommend, propose or announce an intention to authorize, recommend or propose,
or enter into any Contract with respect to, any (i) plan of liquidation or
dissolution, (ii) acquisition of a material amount of assets or securities,
(iii) disposition or Encumbrance of a material amount of assets or securities,
(iv) merger or consolidation or (v) material change in its capitalization;
(h) change any material accounting or Tax procedure or practice;
(i) take any action the taking of which, or omit to take any action
the omission of which, would cause any of the representations and warranties
herein to fail to be true and correct in all material respects as of the date of
such action or omission as though made at and as of the date of such action or
omission;
(j) compromise, settle or otherwise modify any material claim or
litigation not identified in the IBAH Disclosure Schedule; or
------------------------
33
<PAGE>
(k) commit or agree to do any of the foregoing.
Section 7.2. IBAH Stockholder Meeting. IBAH shall cause a meeting of its
------------------------
stockholders (the "IBAH Stockholder Meeting") to be duly called and held as soon
as reasonably practicable for the purpose of voting on the adoption of this
Agreement and the Merger as required by the DGCL. Subject to their fiduciary
duties, the directors of IBAH shall recommend such adoption of this Agreement
and the Merger by IBAH's stockholders. In connection with such meeting, IBAH (a)
will mail to its stockholders as promptly as practicable the Proxy Statement and
all other proxy materials for such meeting, (b) will use all reasonable efforts
to obtain the necessary approvals by its stockholders of this Agreement and the
Transactions, and (c) will otherwise comply with all legal requirements
applicable to such meeting.
Section 7.3. Maintenance of the Assets. IBAH shall, and shall cause each
-------------------------
other IBAH Company to, continue to maintain and service the IBAH Assets
consistent with past practice. IBAH shall not, and shall cause each other IBAH
Company not to, directly or indirectly, sell or encumber all or any part of the
IBAH Assets, other than sales in the ordinary course of business or sales to or
Encumbrances in favor of any other IBAH Company, or initiate or participate in
any discussions or negotiations or enter into any agreement to do any of the
foregoing.
Section 7.4. Employees and Business Relations. IBAH shall, and shall
--------------------------------
cause each other IBAH Company to, use commercially reasonable efforts to keep
available the services of its current employees and agents and to maintain its
relations and goodwill with its suppliers, customers, distributors and any
others having business relations with it.
Section 7.5. Rule 145 Affiliates. No later than 45 days prior to the
-------------------
Effective Time, IBAH shall identify in a letter to Omnicare all Persons who
might, at the time of the IBAH Stockholder Meeting, be deemed to be "affiliates"
of Omnicare for the purposes of Rule 145 under the Securities Act or applicable
pooling standards (the "Securities Act Affiliates"). IBAH shall use
commercially reasonable efforts to cause each Person who is identified as a
possible Securities Act Affiliate to enter into at least 30 days prior to the
Effective Time an agreement in the form of Exhibit A hereto.
Section 7.6. Expenses. Subject to Section 8.2, IBAH shall pay all of the
--------
legal, accounting and other expenses incurred by any IBAH Company in connection
with the Transactions, including any amounts payable to Smith Barney.
Section 7.7. Certain Tax Matters. From the date hereof until the Effective
-------------------
Time, (a) IBAH and each of its Subsidiaries will prepare and file, in the manner
required by applicable Law, all Tax Returns (the "Post-Signing Returns")
required to be filed under applicable Law; (b) IBAH and each of its Subsidiaries
will timely pay all Taxes shown as due and payable on such Post-Signing Returns
that are so filed; (c) IBAH and each of its Subsidiaries will make provision for
all Taxes payable by IBAH and/or any such Subsidiary under applicable Law for
which no Post-Signing Return is due prior to the Effective Time; and (d) IBAH
will promptly notify Omnicare in writing of any action, suit, proceeding, claim
or audit pending against or with respect to IBAH
34
<PAGE>
or any of its Subsidiaries in respect of any Tax that is not disclosed on the
IBAH Disclosure Schedule.
- ------------------------
Section 7.8. Employment Arrangements. IBAH will use commercially
-----------------------
reasonable efforts to cause the Persons listed in Section 7.8 of the IBAH
----
Disclosure Schedule to enter into employment agreements in substantially the
- -------------------
form set forth in Exhibit B hereto, containing the terms set forth opposite such
Person's name in such Section 7.8 of the IBAH Disclosure Schedule.
------------------------
Section 7.9. State Anti-Takeover Law. If any "business combination,"
-----------------------
"moratorium," "control share," "fair price," "interested shareholder,"
"affiliated transaction" or other anti-takeover statute or regulation (including
Section 203 of the DGCL) (i) prohibits or restricts IBAH's ability to perform
its obligations under this Agreement (or any party's ability to perform its
obligations under the Voting Agreement or Stock Option Agreement) or any party's
ability to consummate the Merger or the other transactions contemplated hereby
or thereby, or (ii) would have the effect of invalidating or voiding this
Agreement, the Voting Agreement, Stock Option Agreement or any provision hereof
or thereof, then IBAH shall use its best efforts to obtain any necessary
consents or approvals so that the foregoing shall not apply.
Section 7.10. Preferred and Warrant Consent. At Omnicare's request, IBAH
-----------------------------
will enforce the Preferred and Warrant Consent against the parties thereto. IBAH
will not waive any provisions of such consent. Omnicare may enforce such
consents against the parties thereto to the extent IBAH fails to do so.
ARTICLE VIII
COVENANTS OF OMNICARE
Section 8.1. Appointment to the Board of Directors of Omnicare. At the
-------------------------------------------------
Effective Time, Omnicare shall include Geraldine A. Henwood in its program under
which certain nominations for membership on the Omnicare Board of Directors are
on occasion rotated among senior operating executives of the Omnicare Companies.
Subject to the prior consummation of the Merger, Omnicare shall nominate
Geraldine A. Henwood for election as a director at its 1999 Annual Meeting of
shareholders.
Section 8.2. Expenses. Omnicare shall pay all of the legal, accounting
--------
and other expenses incurred by any Omnicare Company in connection with the
Transactions, including any amounts payable to Morgan Stanley, fees of
Omnicare's transfer agent, fees of the Exchange Agent and fees related to
listing the Omnicare Shares on securities exchanges. The following shall be
paid 50% by IBAH and 50% by Omnicare: SEC filing fees and printing and mailing
costs payable with respect to the Proxy/Registration Statement.
Section 8.3. Indemnification, Directors' and Officers' Insurance. For a
---------------------------------------------------
period of six years after the Effective Time, Omnicare shall cause the Surviving
Corporation to (a) maintain in effect the current provisions regarding
indemnification of officers and directors contained in the Charter Documents and
bylaws of IBAH and in any indemnification agreements of IBAH and (b)
35
<PAGE>
indemnify the directors and officers of IBAH to the fullest extent to which IBAH
is permitted to indemnify such officers and directors under its Charter
Documents and bylaws and applicable Law. For a period of six years after the
Effective Time, Omnicare shall cause the Surviving Corporation to maintain in
effect the current policies of directors' and officers' liability insurance and
fiduciary liability insurance maintained by IBAH (provided that the Surviving
Corporation may substitute therefor policies of at least the same coverage and
amounts containing terms and conditions which are, in the aggregate, no less
advantageous to the insured in any material respect) with respect to claims
arising from facts or events which occurred on or before the Effective Time,
provided that in no event shall Surviving Corporation be required to pay more
than 150% of the current annual premium (which IBAH represents is no more than
$125,000).
Section 8.4. Stock Exchange Listing. Omnicare shall use commercially
----------------------
reasonable efforts to obtain, prior to the Effective Time, the approval for
listing on the NYSE, effective upon official notice of issuance, of the Omnicare
Shares into which the IBAH Shares will be converted pursuant to Article II
hereof and of the Omnicare Shares which will be issuable upon exercise of the
Assumed Options and the Omnicare Warrants to be outstanding at the Effective
Time in accordance with Section 2.8 hereof.
Section 8.5. Interim Financial Report. Omnicare shall provide within 20
------------------------
days after the end of the first full monthly period following the Closing a
financial report regarding the combined operation of Omnicare and IBAH that
satisfies the requirements of Financial Reporting Release No. 1, ASR 135.
Section 8.6. Registration. Omnicare shall take any actions required to be
------------
taken by it following the Effective Time pursuant to the registration rights
provisions contained in the Preferred Stock and Warrant Purchase Agreement dated
August 10, 1995. Within 20 days of the date hereof, IBAH shall deliver to
Omnicare a true and complete list of all agreements which may require Omnicare
to register any securities of IBAH or any Omnicare securities issued in respect
thereof.
Section 8.7. Employee Benefit Plans. Omnicare presently intends to cause
----------------------
the IBAH Companies to provide employee benefit plans which are, in the
aggregate, no less favorable to the employees than current plans.
ARTICLE IX
CONDITIONS PRECEDENT TO OBLIGATIONS OF ALL PARTIES
The respective obligations of each Party to consummate the Merger and the
other Transactions shall be subject to the fulfillment at or prior to the
Effective Time of the following conditions:
Section 9.1. Legality. All required governmental approvals shall have
--------
been obtained and any applicable waiting periods, including those under the HSR
Act, shall have expired. No Law or Court Order shall have been enacted,
entered, promulgated or enforced by any court or governmental entity that is in
effect and that has the effect of making the Merger illegal or
36
<PAGE>
otherwise prohibiting the consummation of the Merger and no legal action shall
be pending or threatened which is reasonably likely to have a Material Adverse
Effect on either Party.
Section 9.2. Registration Statement. The Registration Statement shall
----------------------
have become effective under the Securities Act, no stop order suspending the
effectiveness of the Registration Statement shall have been issued, and no
proceedings for that purpose shall have been instituted.
Section 9.3. New York Stock Exchange. The Omnicare Shares issuable in
-----------------------
connection with the Transactions shall have been duly approved for listing on
the NYSE, subject to official notice of issuance.
Section 9.4. Pooling. IBAH shall receive a poolability letter from Arthur
-------
Andersen LLP dated as of the Closing Date to the effect that IBAH qualifies as a
combining company, as the term is used in Accounting Principles Board Opinion
No. 16 ("APB 16") to describe the criteria necessary for the use of the pooling
of interest method of accounting. Omnicare shall receive a pooling letter from
Price Waterhouse LLP dated as of the Closing Date to the effect that Omnicare
and the Transactions qualify for pooling of interest accounting treatment as
defined in APB 16.
Section 9.5. Approval by IBAH Stockholders. This Agreement shall have
-----------------------------
been approved and adopted by the stockholders of IBAH in accordance with the
DGCL and its Charter Documents.
Section 9.6. Tax Opinions. Omnicare shall have received an opinion of
------------
Omnicare's counsel, in form and substance reasonably satisfactory to Omnicare,
and IBAH shall have received an opinion of IBAH's counsel, in form and substance
reasonably satisfactory to IBAH, each dated as of the Closing Date, to the
effect that the Merger will constitute a reorganization within the meaning of
Code Section 368(a) and that Omnicare, Merger Subsidiary and IBAH shall each be
a party to that reorganization within the meaning of Code Section 368(b). In
rendering such tax opinions, such counsel may require and rely upon reasonably
requested representations contained in certificates of Omnicare, IBAH and Merger
Subsidiary.
ARTICLE X
CONDITIONS PRECEDENT TO OBLIGATIONS OF IBAH
The obligations of IBAH to consummate the Merger and the Transactions shall
be subject to the satisfaction or waiver, on or before the Effective Time, of
each of the following conditions:
Section 10.1. Representations and Warranties. The representations and
------------------------------
warranties of the Omnicare Parties contained in this Agreement shall be true and
correct on the date hereof and (except to the extent such representations and
warranties speak as of an earlier date) shall also be true and correct on and as
of the Closing Date, except for changes contemplated by this Agreement, with the
same force and effect as if made on and as of the Closing Date; provided,
however, that for purposes of this Section 10.1 only, such representations and
warranties shall be
37
<PAGE>
deemed to be true and correct unless the failure or failures of such
representations and warranties to be so true and correct (without regard to
materiality qualifiers contained therein), individually or in the aggregate,
results or would reasonably be expected to result in a Material Adverse Effect
on Omnicare.
Section 10.2. Agreements, Conditions and Covenants. The Omnicare Parties
------------------------------------
shall have performed or complied in all material respects with all agreements,
conditions and covenants required by this Agreement to be performed or complied
with by them on or before the Effective Time.
Section 10.3. Certificates. IBAH shall have received a certificate of an
------------
executive officer of Omnicare to the effect set forth in Sections 10.1 and 10.2.
Section 10.4. Material Adverse Effect. There shall have been no Material
-----------------------
Adverse Effect on the Omnicare Companies taken as a whole.
Section 10.5. Ancillary Documents. Each Omnicare Party shall have
-------------------
tendered executed copies of the respective Transaction Documents to which it is
intended to be a party, including the Employment Agreements, Voting Agreements
and the Stock Option Agreement.
ARTICLE XI
CONDITIONS PRECEDENT TO OBLIGATIONS OF THE OMNICARE PARTIES
The obligations of the Omnicare Parties to consummate the Merger and the
Transactions shall be subject to the satisfaction or waiver, on or before the
Effective Time, of each of the following conditions:
Section 11.1. Representations and Warranties. The representations and
------------------------------
warranties of IBAH contained in this Agreement shall be true and correct on the
date hereof and (except to the extent such representations and warranties speak
as of an earlier date) shall also be true and correct on and as of the Closing
Date, except for changes contemplated by this Agreement, with the same force and
effect as if made on and as of the Closing Date; provided, however, that for
purposes of this Section 11.1 only, such representations and warranties shall be
deemed to be true and correct unless the failure or failures of such
representations and warranties to be so true and correct (without regard to
materiality qualifiers contained therein), individually or in the aggregate,
results or would reasonably be expected to result in a Material Adverse Effect
on IBAH.
Section 11.2. Agreements, Conditions and Covenants. IBAH shall have
------------------------------------
performed or complied in all material respects with all agreements, conditions
and covenants required by this Agreement to be performed or complied with by it
on or before the Effective Time.
Section 11.3. Certificates. Omnicare shall have received a certificate of
------------
an executive officer of IBAH to the effect set forth in Sections 11.1 and 11.2.
38
<PAGE>
Section 11.4. Required Consents. IBAH shall have obtained all consents
-----------------
from third parties listed in Section 4.3 of the IBAH Disclosure Schedule and all
------------------------
other consents the absence of which would result in a Material Adverse Effect.
Section 11.5. Material Adverse Effect. There shall have been no Material
-----------------------
Adverse Effect on the IBAH Companies taken as a whole.
Section 11.6. Ancillary Documents. IBAH shall have tendered executed
-------------------
copies of the Transaction Documents to which it is intended to be a party.
Section 11.7. Consent of Holders of IBAH Preferred Shares and IBAH
----------------------------------------------------
Warrants. The consents of the Holders of IBAH Preferred Shares and IBAH Warrants
- --------
described in Sections 2.8 and 4.2 shall have been received by IBAH prior to the
Effective Time, or if such consents have not been received at or prior to the
Effective Time, all such Holders shall have approved the Transactions.
Section 11.8. Employment Agreements. Each Person listed in Section 7.8 of
---------------------
the IBAH Disclosure Schedule shall have entered into an Employment Agreement as
------------------------
contemplated by Section 7.8.
ARTICLE XII
TERMINATION
Section 12.1. Grounds for Termination. This Agreement may be terminated
-----------------------
at any time before the Effective Time, in each case as authorized by the
respective Boards of Directors of Omnicare and IBAH:
(a) By mutual written consent of each of Omnicare and IBAH;
(b) By either Omnicare or IBAH if the Merger shall not have been
consummated on or before the Termination Date; provided, however, that the right
to terminate this Agreement under this Section 12.1(b) shall not be available to
any Party whose failure to fulfill any obligation under this Agreement has been
the cause of, or resulted in, the failure of the Effective Time to occur on or
before the Termination Date;
(c) By either Omnicare or IBAH if a court of competent jurisdiction
or governmental, regulatory or administrative agency or commission shall have
issued a Court Order (which Court Order the Parties shall use commercially
reasonable efforts to lift) that permanently restrains, enjoins or otherwise
prohibits the Transactions, and such Court Order shall have become final and
nonappealable;
(d) By Omnicare if IBAH shall have breached, or failed to comply
with, in any material respect, any of its obligations under this Agreement or
any representation or warranty
39
<PAGE>
made by IBAH shall have been incorrect in any material respect when made, and
such breach, failure or misrepresentation is not cured within 20 days after
notice thereof, and in either case, any such breaches, failures or
misrepresentations, individually or in the aggregate, results or would
reasonably be expected to result in a failure to satisfy a condition to IBAH's
obligations to consummate the transactions contemplated hereby;
(e) By IBAH if any Omnicare Party shall have breached, or failed to
comply with, in any material respect, any of its obligations under this
Agreement or any representation or warranty made by it shall have been incorrect
in any material respect when made, and such breach, failure or misrepresentation
is not cured within 20 days after notice thereof, and in either case, any such
breaches, failures or misrepresentations, individually or in the aggregate,
results or would reasonably be expected to result in a failure to satisfy a
condition to Omnicare's obligations to consummate the transactions contemplated
hereby;
(f) By IBAH if at the IBAH Stockholder Meeting (including any
adjournment thereof) this Agreement and the Merger shall fail to be approved and
adopted by the affirmative vote of the stockholders of IBAH as required under
the DGCL;
(g) By IBAH, prior to the approval of this Agreement by the
stockholders of IBAH, upon five days notice to Omnicare, if, as a result of an
Acquisition Proposal received by IBAH from a Person other than a Party to this
Agreement or any of its Affiliates, the Board of Directors of IBAH determines in
good faith that its fiduciary obligations under applicable Law require that such
Acquisition Proposal be accepted; provided, however, that (i) immediately
following such termination IBAH executes with such third party a definitive
agreement to implement such Acquisition Proposal, (ii) the Board of Directors of
IBAH shall have concluded in good faith, after considering applicable provisions
of applicable Law and after giving effect to all concessions which may be
offered by Omnicare pursuant to clause (iii) below, on the basis of advice of
counsel, that such action is necessary for the Board of Directors to act in a
manner consistent with its fiduciary duties under applicable Law, (iii) prior to
any such termination, (x) IBAH shall have provided Omnicare with five days'
notice of the terms of the proposal and otherwise complied with Section 6.3
hereof (including making the finding contemplated by Section 6.3(i)(x) hereof)
and (y) IBAH shall, and shall cause its financial and legal advisors to,
negotiate with Omnicare to make such adjustments in the terms and conditions of
this Agreement as would enable IBAH to proceed with the Transactions and (iv)
IBAH shall have paid Omnicare the Termination Fee; or
(h) By Omnicare if the Board of Directors of IBAH shall withdraw,
modify or change its recommendation of this Agreement or the Merger or shall
have failed to reaffirm its recommendation within five business days of
Omnicare's request that it do so or shall have recommended or issued a neutral
recommendation (or taken no position) with respect to any Acquisition Proposal.
(i) By IBAH, pursuant to Section 2.6(c) hereof.
40
<PAGE>
Section 12.2. Effect of Termination.
---------------------
(a) If this Agreement is terminated pursuant to Section 12.1, this
Agreement shall forthwith become void and there shall be no liability on the
part of any of the Parties; notwithstanding the foregoing, nothing herein shall
relieve any Party from liability for any willful breach hereof; provided that
the provisions of Sections 6.3, 6.5(b), 7.6, 7.10, 8.2 and this Section 12.2
shall survive the termination hereof.
(b) If following an Acquisition Proposal, this Agreement is
terminated by either Omnicare or IBAH pursuant to Section 12.1(b), and within 12
months after such termination IBAH executes with a third party a definitive
agreement to implement an Acquisition Proposal, then IBAH shall pay to Omnicare
a Termination Fee within two business days after the execution of such
agreement.
(c) If this Agreement is terminated by Omnicare pursuant to Section
12.1(d), then IBAH shall reimburse Omnicare for its reasonable out-of-pocket
expenses in connection with the Transactions, including, without limitation,
attorneys', accountants' and investment bankers' fees and expenses ("Transaction
Fees") up to an aggregate of $1,500,000. If within 12 months after such
termination IBAH executes with a third party a definitive agreement to implement
an Acquisition Proposal, then IBAH shall pay to Omnicare a Termination Fee (less
any Transaction Fees previously paid to Omnicare) within two business days after
the execution of such agreement.
(d) If this Agreement is terminated by IBAH pursuant to Section
12.1(e), then Omnicare shall reimburse IBAH for its Transaction Fees up to an
aggregate of $1,500,000.
(e) If following an Acquisition Proposal, this Agreement is
terminated by either Omnicare or IBAH pursuant to Section 12.1(f), and within 12
months after such termination IBAH executes with a third party a definitive
agreement to implement an Acquisition Proposal, then IBAH shall pay to Omnicare
a Termination Fee within two business days after the execution of such
agreement.
(f) If this Agreement is terminated by IBAH pursuant to Section
12.1(g), then IBAH shall pay to Omnicare a Termination Fee prior to such
termination.
(g) If this Agreement is terminated by Omnicare pursuant to Section
12.1(h), then IBAH shall pay to Omnicare a Termination Fee within two business
days after the execution of such agreement.
(h) For purposes of this Section 12.2(b), "Termination Fee" shall
mean $5 million for the period from the termination of the Agreement until the
Option Termination Date (as defined in the Stock Option Agreement) and $8.366
million for the period, if any, after the Option Termination Date until 12
months after the termination of the Agreement.
41
<PAGE>
IBAH acknowledges that the agreements contained in this Section 12.2 are an
integral part of the Transactions, and that, without these agreements, Omnicare
would not enter into this Agreement; accordingly, if IBAH fails to promptly pay
the amount due pursuant to this Section 12.2, and, in order to obtain such
payment, Omnicare commences a suit which results in a judgment against IBAH for
the fee set forth in this Section 12.2, IBAH shall pay to Omnicare its costs and
expenses (including reasonable attorneys' fees) in connection with such suit,
together with interest on the amount of the fee at a rate equal to the prime
rate of First Chicago NBD at the time of payment from the date such fee was
required to be paid.
ARTICLE XIII
GENERAL MATTERS
Section 13.1. Survival of Representations and Warranties. The
------------------------------------------
representations and warranties in this Agreement shall terminate at the
Effective Time or upon the termination of this Agreement pursuant to Section
12.1.
Section 13.2. Contents of Agreement. This Agreement and the
---------------------
Confidentiality Agreement, together with the other Transaction Documents, set
forth the entire understanding of the Parties hereto with respect to the
Transactions and supersede all prior agreements or understandings among the
Parties regarding those matters.
Section 13.3. Amendment, Parties in Interest, Assignment, Etc. This
------------------------------------------------
Agreement may be amended, modified or supplemented only by a written instrument
duly executed by each of the Parties hereto. If any provision of this Agreement
shall for any reason be held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality or unenforceability shall not affect any
other provision hereof, and this Agreement shall be construed as if such
invalid, illegal or unenforceable provision had never been contained herein.
This Agreement shall be binding upon and inure to the benefit of and be
enforceable by the respective heirs, legal representatives, successors and
permitted assigns of the Parties hereto. No Party hereto shall assign this
Agreement or any right, benefit or obligation hereunder. Any term or provision
of this Agreement may be waived at any time by the Party entitled to the benefit
thereof by a written instrument duly executed by such Party. The Parties hereto
shall execute and deliver any and all documents and take any and all other
actions that may be deemed reasonably necessary by their respective counsel to
complete the Transactions. Nothing in this Agreement is intended or will be
construed to confer on any Person other than the Parties hereto any rights or
benefits hereunder.
Section 13.4. Interpretation. Unless the context of this Agreement
--------------
clearly requires otherwise, (a) references to the plural include the singular,
the singular the plural, the part the whole, (b) references to any gender
include all genders, (c) "or" has the inclusive meaning frequently identified
with the phrase "and/or," (d) "including," "includes" or similar words has the
inclusive meaning frequently identified with the phrase "but not limited to" and
(e) references to "hereunder" or "herein" relate to this Agreement. The section
and other headings contained in this Agreement are for reference purposes only
and shall not control or affect the construction of this Agreement or the
interpretation thereof in any respect. Section, subsection, Disclosure
42
<PAGE>
Schedule and Exhibit references are to this Agreement unless otherwise
specified. The Exhibits and Schedules referred to in this Agreement will be
deemed to be a part of this Agreement. Each accounting term used herein that is
not specifically defined herein shall have the meaning given to it under GAAP.
Section 13.5. Notices. All notices that are required or permitted
-------
hereunder shall be in writing and shall be sufficient if personally delivered or
sent by mail, facsimile message or Federal Express or other delivery service.
Any notices shall be deemed given upon receipt at the address or fax number set
forth below, unless such address or fax number is changed by notice to the other
Party hereto:
If to Omnicare or Merger Subsidiary:
Omnicare, Inc.
2800 Chemed Center
255 East Fifth Street
Cincinnati, Ohio 45203
FAX: 513-762-6678
Attention: Cheryl D. Hodges
with a required copy to:
Dewey Ballantine LLP
1301 Avenue of the Americas
New York, New York 10019
FAX: 212-259-6333
Attention: Morton A. Pierce and Richard D. Pritz
If to IBAH:
IBAH, Inc.
Four Valley Square
512 Township Line Road
Blue Bell, PA 19422
FAX: 215-542-2726
Attention: Jane Hollingsworth
with a required copy to:
Morgan, Lewis & Bockius LLP
2000 One Logan Square
Philadelphia, PA 19103-6993
FAX: 215-963-5299
Attention: Thomas J. Sharbaugh, Esquire
43
<PAGE>
Section 13.6. Governing Law. This Agreement shall be construed and
-------------
interpreted in accordance with the Laws of the State of Delaware without regard
to its provisions concerning conflict of laws.
Section 13.7. Counterparts. This Agreement may be executed in two or more
------------
counterparts, each of which shall be binding as of the date first written above,
and all of which shall constitute one and the same instrument. Each such copy
shall be deemed an original, and it shall not be necessary in making proof of
this Agreement to produce or account for more than one such counterpart.
Section 13.8. Waivers. Compliance with the provisions of this Agreement
-------
may be waived only by a written instrument specifically referring to this
Agreement and signed by the Party waiving compliance. No course of dealing, nor
any failure or delay in exercising any right, will be construed as a waiver, and
no single or partial exercise of a right will preclude any other or further
exercise of that or any other right.
Section 13.9. Modification. No supplement, modification or amendment of
------------
this Agreement will be binding unless made in a written instrument that is
signed by all of the Parties hereto and that specifically refers to this
Agreement.
Section 13.10. Enforcement of Agreement. The parties hereto agree that
------------------------
irreparable damage would occur in the event that any of the provisions of this
Agreement was not performed in accordance with its specific terms or was
otherwise breached. It is accordingly agreed that the parties shall be entitled
to an injunction to prevent breaches of this Agreement and to enforce
specifically the terms and provisions hereof in any Delaware Chancery Court,
this being in addition to any other remedy to which they are entitled at law or
equity. Notwithstanding the foregoing, if jurisdiction does not properly lie in
the Delaware Chancery Court, the parties shall submit to the jurisdiction of
Delaware federal courts. The parties agree that such courts shall have
exclusive jurisdiction to consider any claims hereunder or relating hereto.
Section 13.11. Waiver of Jury Trial. Each party acknowledges and agrees
--------------------
that any controversy which may arise under this Agreement is likely to involve
complicated and difficult issues, and therefore each such party hereby
irrevocably and unconditionally waives any right such party may have to a trial
by jury in respect of any litigation directly or indirectly arising out of or
relating to this Agreement, or the Transactions contemplated by this Agreement.
Each party certifies and acknowledges that (i) no representative, agent or
attorney of any other party has represented, expressly or otherwise, that such
other party would not, in the event of litigation, seek to enforce the foregoing
waiver, (ii) each party understands and has considered the implications of this
waiver, (iii) each party makes this waiver voluntarily, and (iv) each party has
been induced to enter into this Agreement by, among other things, the mutual
waivers and certifications in this Section 13.11.
Section 13.12. Severability. If any term or other provision of this
------------
Agreement is invalid, illegal or incapable of being enforced by any rule of law
or public policy, all other conditions and provisions of this Agreement shall
nevertheless remain in full force and effect. Upon such
44
<PAGE>
determination that any term or other provision is invalid, illegal or incapable
of being enforced, the parties hereto shall negotiate in good faith to modify
this Agreement so as to effect the original intent of the parties as closely as
possible to the fullest extent permitted by applicable Law in an acceptable
manner to the end that the Transactions are fulfilled to the extent possible.
45
<PAGE>
IN WITNESS WHEREOF, this Agreement has been executed by the Parties hereto
as of the day and year first written above.
OMNICARE, INC.
By: /s/ Joel F. Gemunder
-------------------------------
Name: Joel F. Gemunder
Title: President
IMPALA ACQUISITION CORP.
By: /s/ L. Tracy Finn
-------------------------------
Name: L. Tracy Finn
Title: President
IBAH, INC.
By: /s/ Geraldine A. Henwood
--------------------------------
Name: Geraldine A. Henwood
Title: Chief Executive Officer
46
<PAGE>
EXHIBIT 2.2
-----------
STOCK OPTION AGREEMENT
STOCK OPTION AGREEMENT, dated as of March 30, 1998 (the "Agreement"),
between Omnicare, Inc. a Delaware corporation ("Grantee"), and IBAH, Inc., a
Delaware corporation ("Grantor").
WHEREAS, Grantee and Grantor are entering into an Agreement and Plan
of Merger, dated as of the date hereof (the "Merger Agreement"), which provides,
among other things, for the merger of Grantor with and into a wholly owned
subsidiary of Grantee (the "Merger");
WHEREAS, as a condition to their willingness to enter into the Merger
Agreement, Grantee has requested that Grantor grant to Grantee an option to
purchase up to 4,685,315 (the "Option Number") shares of Common Stock, par value
$0.01 per share, of Grantor (the "Common Stock"), upon the terms and subject to
the conditions hereof; and
WHEREAS, in order to induce Grantee to enter into the Merger
Agreement, Grantor is willing to grant Grantee the requested option.
NOW, THEREFORE, in consideration of the premises and the mutual
covenants and agreements set forth herein, the parties hereto agree as follows:
1. The Option; Exercise; Adjustments; Payment of Spread.
----------------------------------------------------
(a) Subject to the other terms and conditions set forth herein, Grantor
hereby grants to Grantee an irrevocable option (the "Option") to purchase up to
the Option Number shares of Common Stock (the "Shares") at a cash purchase price
equal to $5.75 per share (the "Purchase Price"). The Option may be exercised by
Grantee, in whole or in part, at any time, or from time to time, following the
occurrence of one of the events set forth in Section 2(c) hereof, and prior to
the termination of the Option in accordance with the terms of this Agreement.
(b) In the event Grantee wishes to exercise the Option, Grantee shall
send a written notice to Grantor (the "Stock Exercise Notice") specifying a date
(subject to the HSR Act, as defined below) not later than 10 business days and
not earlier than three business days following the date such notice is given for
the closing of such purchase. In the event of any change in the number of issued
and outstanding shares of Common Stock by reason of any stock dividend, stock
split, split-up, recapitalization, merger or other change in the corporate or
capital structure of Grantor, the number of Shares subject to this Option and
the purchase price per Share shall be appropriately adjusted to restore Grantee
to its rights hereunder, including its right to purchase Shares representing
19.9% of the capital stock of Grantor entitled to vote generally for the
election of the directors of Grantor which is issued and outstanding immediately
prior to the exercise of the Option
<PAGE>
at an aggregate purchase price equal to the Purchase Price multiplied by the
Option Number.
(c) If at any time the Option is then exercisable pursuant to the
terms of Section 1(a) hereof, Grantee may elect, in lieu of exercising the
Option to purchase Shares provided in Section 1(a) hereof, to send a written
notice to Grantor (the "Cash Exercise Notice") specifying a date not later than
20 business days and not earlier than 10 business days following the date such
notice is given on which date Grantor shall pay to Grantee an amount in cash
equal to the Spread (as hereinafter defined) multiplied by all or such portion
of the Shares subject to the Option as Grantee shall specify. As used herein
"Spread" shall mean the excess, if any, over the Purchase Price of the higher of
(x) if applicable, the highest price per share of Common Stock (including any
brokerage commissions, transfer taxes and soliciting dealers' fees) paid or
proposed to be paid by any person pursuant to one of the transactions enumerated
in Section 2(c) hereof (the "Alternative Purchase Price") or (y) the average of
the closing prices (or the average of the closing bid and asked prices if
closing prices are unavailable) of the shares of Common Stock as reported on
Nasdaq on the last trading day immediately prior to the date of the Cash
Exercise Notice (the "Closing Price"). If the Alternative Purchase Price
includes any property other than cash, the Alternative Purchase Price shall be
the sum of (i) the fixed cash amount, if any, included in the Alternative
Purchase Price plus (ii) the fair market value of such other property. If such
other property consists of securities with an existing public trading market,
the average of the closing prices (or the average of the closing bid and asked
prices if closing prices are unavailable) for such securities in their principal
public trading market on the five trading days ending five days prior to the
date of the Cash Exercise Notice shall be deemed to equal the fair market value
of such property. If such other property consists of something other than cash
or securities with an existng public trading market and, as of the payment date
for the Spread, agreement on the value of such other property has not been
reached, the Alternative Purchase Price shall be deemed to equal the Closing
Price. Upon exercise of its right to receive cash pursuant to this Section 1(c),
the obligations of Grantor to deliver Shares pursuant to Section 3 shall be
terminated with respect to such number of Shares for which Grantee shall have
elected to be paid the Spread.
2. Conditions to Delivery of Shares. The Grantor's obligation to
--------------------------------
deliver Shares upon exercise of the Option is subject only to the conditions
that:
(a) No preliminary or permanent injunction or other order issued by
any federal or state court of competent jurisdiction in the United States
prohibiting the delivery of the Shares shall be in effect; and
(b) Any applicable waiting periods under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976 (the "HSR Act") shall have expired or
been terminated; and
(c) (i) any person (other than Grantee or any of its subsidiaries)
shall have commenced (as such term is defined in Rule 14d-2 under the
Securities Exchange
2
<PAGE>
Act of 1934 (the "Exchange Act")) a tender offer, or shall have filed a
registration statement under the Securities Act of 1933 (the "Securities
Act") with respect to an exchange offer, to purchase any shares of Common
Stock such that, upon consummation of such offer, such person or a "group"
(as such term is defined under the Exchange Act) of which such person is a
member shall have acquired beneficial ownership (as such term is defined in
Rule 13d-3 of the Exchange Act), or the right to acquire beneficial
ownership, of 25% or more of the then outstanding Common Stock; (ii) any
person (other than Grantee or any of its subsidiaries) shall have publicly
announced or delivered to Grantor a proposal, or disclosed publicly or to
Grantor an intention to make a proposal, to purchase 25% or more of the
assets or any equity securities of, or to engage in a merger,
reorganization, tender offer, share exchange, consolidation or similar
transaction involving the Grantor or any of its subsidiaries (an
"Acquisition Transaction"); (iii) Grantor or any of its subsidiaries shall
have authorized, recommended, proposed or publicly announced an intention
to authorize, recommend or propose, or entered into, an agreement,
including without limitation, an agreement in principle, with any person
(other than Grantee or any of its subsidiaries) to effect or provide for an
Acquisition Transition; (iv) any person (other than Grantee or any of its
subsidiaries) shall solicit proxies or consents or announce a bona fide
intention to solicit proxies or consents from Grantor's stockholders (y) in
opposition to the Merger, the Merger Agreement or any related transactions
or (z) relating to an Acquisition Transaction (other than solicitations of
stockholders seeking approval of the Merger, the Merger Agreement or any
related transactions), and the stockholders of the Company shall have
failed to approve the Merger; or (v) any person (other than Grantee or any
of its subsidiaries) shall have acquired beneficial ownership (as such term
is defined in Rule 13d-3 under the Exchange Act) or the right to acquire
beneficial ownership of, or any "group" (as such term is defined under the
Exchange Act) shall have been formed which beneficially owns or has the
right to acquire beneficial ownership of, shares of Common Stock (other
than trust account shares) aggregating 25% or more of the then outstanding
Common Stock. As used in this Agreement, "person" shall have the meaning
specified in Sections 3(a)(9) and 13(d)(3) of the Exchange Act.
3. The Closing. (a) Any closing hereunder shall take place on the date
-----------
specified by Grantee in its Stock Exercise Notice or Cash Exercise Notice, as
the case may be, at 9:00 a.m., local time, at the offices of Dewey Ballantine
LLP, 1301 Avenue of the Americas, New York, New York, or, if the conditions set
forth in Section 2(a) or (b) have not then been satisfied, on the second
business day following the satisfaction of such conditions, or at such other
time and place as the parties hereto may agree (the "Closing Date"). On the
Closing Date, (i) in the event of a closing pursuant to Section 1(b) hereof,
Grantor will deliver to Grantee a certificate or certificates, representing the
Shares in the denominations designated by Grantee in its Stock Exercise Notice
and Grantee will purchase such Shares from Grantor at the price per Share equal
to the Purchase Price or (ii) in the event of a closing pursuant to Section 1(c)
hereof, Grantor will deliver to Grantee cash in an amount determined pursuant to
Section 1(c) hereof. Any payment
3
<PAGE>
made by Grantee to Grantor, or by Grantor to Grantee, pursuant to this Agreement
shall be made by certified or official bank check or by wire transfer of
immediately available funds to a bank designated by the party receiving such
funds.
(b) The certificates representing the Shares shall bear an appropriate
legend relating to the fact that such Shares have not been registered under the
Securities Act.
4. Representations and Warranties of Grantor. The Grantor represents
-----------------------------------------
and warrants to Grantee that (a) Grantor is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware
and has the requisite corporate power and authority to enter into and perform
this Agreement; (b) the execution and delivery of this Agreement by Grantor and
the consummation by it of the transactions contemplated hereby have been duly
authorized by the Board of Directors of Grantor and this Agreement has been duly
executed and delivered by a duly authorized officer of Grantor and constitutes a
valid and binding obligation of Grantor, enforceable in accordance with its
terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability relating to or affecting
creditors' rights and to general equity principles; (c) Grantor has taken all
necessary corporate action to authorize and reserve the Shares issuable upon
exercise of the Option and the Shares, when issued and delivered by Grantor upon
exercise of the Option and paid for by Grantee as contemplated hereby, will be
duly authorized, validly issued, fully paid and non-assessable and free of
preemptive rights; (d) except as otherwise required by the HSR Act, the
execution and delivery of this Agreement by Grantor and the consummation by it
of the transactions contemplated hereby do not require the consent, waiver,
approval or authorization of or any filing with any person or public authority
and will not violate, result in a breach of or the acceleration of any
obligation under, or constitute a default under, any provision of Grantor's
charter or by-laws, or any material indenture, mortgage, lien, lease, agreement,
contract, instrument, order, law, rule, regulation, judgment, ordinance, or
decree, or restriction by which Grantor or any of its subsidiaries or any of
their respective properties or assets is bound; (e) Grantor (i) will not,
through reorganization, consolidation, merger, dissolution or sale of assets, or
by any other voluntary act, avoid or seek to avoid the observance or performance
of any of the covenants, stipulations or conditions to be observed or performed
hereunder by Grantor and (ii) will promptly take all action provided herein to
protects the rights of Grantee against dilution as set forth in Section 1(b)
hereof and (f) no "fair price", "moratorium", "control share acquisition,"
"interested shareholder" or other form of antitakeover statute or regulation,
including without limitation, Section 203 of the Delaware General Corporation
Act, or similar provision contained in the charter or by-laws of Grantor, is or
shall be applicable to the acquisition of Shares pursuant to this Agreement.
5. Representations and Warranties of Grantee. The Grantee represents
-----------------------------------------
and warrants to Grantor that (a) the execution and delivery of this Agreement by
Grantee and the consummation by it of the transactions contemplated hereby have
been duly authorized by all necessary corporate action on the part of Grantee
and this Agreement has been duly executed and delivered by a duly authorized
officer of Grantee and
4
<PAGE>
constitutes a valid and binding obligation of Grantee; and (b) Grantee is
acquiring the Option and, if and when it exercises the Option, will be acquiring
the Shares issuable upon the exercise thereof for its own account and not with a
view to distribution or resale in any manner which would be in violation of the
Securities Act.
6. Listing of Shares; Filings; Governmental Consents. Grantor will
-------------------------------------------------
promptly file an application to list the Shares on the Nasdaq National Market
("Nasdaq") and will use its reasonable best efforts to obtain approval of such
listing and to effect all necessary filings by Grantor under the HSR Act;
provided, however, that if Grantor is unable to effect such listing on Nasdaq by
the Closing Date, Grantor will nevertheless be obligated to deliver the Shares
upon the Closing Date. Each of the parties hereto will use its reasonable best
efforts to obtain consents of all third parties and governmental authorities, if
any, necessary to the consummation of the transactions contemplated.
7. Sale of Shares. At any time prior to the first anniversary of the
--------------
termination of the Merger Agreement in accordance with its terms (such
anniversary, the "Merger Termination Date"), Grantee shall have the right to
sell (the "Sale Right") to Grantor all, but not less than all, of the Shares at
the average of the last sales prices for shares of Common Stock on the ten
trading days ending five days prior to the date Grantee gives written notice of
its intention to exercise the Sale Right. If Grantee does not exercise the Sale
Right prior to the first anniversary of the Merger Termination Date, the Sale
Right terminates. In the event Grantee wishes to exercise the Sale Right,
Grantee shall send a written notice to Grantor specifying a date not later than
20 business days and not earlier than 10 business days following the date such
notice is given for the closing of such sale.
8. Registration Rights. (a) In the event that Grantee shall desire to
-------------------
sell any of the Shares, Grantor will cooperate with Grantee and any underwriters
in registering such Shares for resale, including, without limitation, promptly
filing a registration statement which complies with the requirements of
applicable federal and state securities laws, and entering into an underwriting
agreement with such underwriters upon such terms and conditions as are
customarily contained in underwriting agreements with respect to secondary
distributions; provided that Grantor shall not be required to have declared
effective more than two registration statements hereunder and shall be entitled
to delay the filing or effectiveness of any registration statement for up to 60
days if the offering would, in the judgment of the Board of Directors of
Grantor, require premature disclosure of any material corporate development or
material transaction involving Grantor or interfere with any previously planned
securities offering by the Company. Grantee shall use reasonable efforts to
cause, and to cause any underwriters of any sale or other disposition to use
reasonable efforts to cause, any sale or other disposition pursuant to such
registration statement to be effected on a widely distributed basis.
(b) If the Common Stock is registered pursuant to the provisions of
this Section 8, Grantor agrees (i) to furnish copies of the registration
statement and the prospectus relating to the Shares covered thereby in such
numbers as Grantee may from time to time reasonably request and (ii) if any
event shall occur as a result of which it becomes necessary to amend or
supplement any registration statement or prospectus, to prepare
5
<PAGE>
and file under the applicable securities laws such amendments and supplements as
may be necessary to keep available for at least 45 days a prospectus covering
the Common Stock meeting the requirements of such securities laws, and to
furnish Grantee such numbers of copies of the registration statement and
prospectus as amended or supplemented as may reasonably be requested. The
Grantor shall bear the cost of the registration, including, but not limited to,
all registration and filing fees, printing expenses, and fees and disbursements
of counsel and accountants for Grantor, except that Grantee shall pay the fees
and disbursements of its counsel, and the underwriting fees and selling
commissions applicable to the shares of Common Stock sold by Grantee. The
Grantor shall indemnify and hold harmless (i) Grantee, its affiliates and its
officers and directors and (ii) each underwriter and each person who controls
any underwriter within the meaning of the Securities Act or the Exchange Act
(collectively, the "Underwriters") ((i) and (ii) being referred to as
"Indemnified Parties") against any losses, claims, damages, liabilities or
expenses, to which the Indemnified Parties may become subject, insofar as such
losses, claims, damages, liabilities (or actions in respect thereof) and
expenses arise out of or are based upon any untrue statement or alleged untrue
statement of any material fact contained or incorporated by reference in any
registration statement filed pursuant to this paragraph, or arise out of or are
based upon the omission or alleged omission to state therein a material
factrequired to be stated therein or necessary to make the statements therein
not misleading; provided, however, that Grantor will not be liable in any such
case to the extent that any such loss, liability, claim, damage or expense
arises out of or is based upon an untrue statement or alleged untrue statement
in or omission or alleged omission from any such documents in reliance upon and
in conformity with written information furnished to Grantor by the Indemnified
Parties expressly for use or incorporation by reference therein.
(c) The Grantee and the Underwriters shall indemnify and hold harmless
Grantor, its affiliates and its officers and directors against any losses,
claims, damages, liabilities or expenses to which Grantor, its affiliates and
its officers and directors may become subject, insofar as such losses, claims,
damages, liabilities (or actions in respect thereof) and expenses arise out of
or are based upon any untrue statement of any material fact contained or
incorporated by reference in any registration statement filed pursuant to this
paragraph, or arise out of or are based upon the omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading, in each case to the extent, but only to
the extent, that such untrue statement or alleged untrue statement or omission
or alleged omission was made in reliance upon and in conformity with written
information furnished to Grantor by Grantee or the Underwriters, as applicable,
specifically for use or incorporation by reference therein.
9. Expenses. Each party hereto shall pay its own expenses incurred in
--------
connection with this Agreement, except as otherwise specifically provided
herein.
10. Specific Performance. The Grantor acknowledges that if Grantor
--------------------
fails to perform any of its obligations under this Agreement immediate and
irreparable harm or injury would be caused to Grantee for which money damages
would not be an adequate
6
<PAGE>
remedy. In such event, Grantor agrees that Grantee shall have the right, in
addition to any other rights it may have, to specific performance of this
Agreement.
11. Notice. All notices, requests, demands and other communications
------
hereunder shall be in writing deemed to have been duly given upon receipt by the
person at the address set forth below, or such other address as may be
designated in writing hereafter, in the same manner, by such person:
If to Grantee:
Attention:
Telecopy:
With a copy to:
Dewey Ballantine LLP
1301 Avenue of the Americas
New York, New York 10019
Attn: Morton A. Pierce and Richard D. Pritz
Telecopy: (212) 259-6333
If to Grantor:
Attention:
Telecopy:
With a copy to:
Morgan, Lewis & Bockius LLP
2000 One Logan Square
Philadelphia, Pennsylvania 19103
Attn: Thomas J. Sharbaugh
Telecopy: (215) 963-5299
12. Parties in Interest. This Agreement shall inure to the benefit of
-------------------
and be binding upon the parties named herein and their respective successors and
assigns; provided, however, that such successor in interest or assigns shall
agree to be bound by the provisions of this Agreement. Nothing in this
Agreement, express or implied, is intended to confer upon any person other than
Grantor or Grantee, or their successors or assigns, any rights or remedies under
or by reason of this Agreement.
13. Entire Agreement; Amendments. This Agreement, together with the
----------------------------
Merger Agreement and the other documents referred to therein, contains the
entire agreement between the parties hereto with respect to the subject matter
hereof and supersedes all prior and contemporaneous agreements and
understandings, oral or written, with respect to such transactions. This
Agreement may not be changed, amended or modified orally,
7
<PAGE>
but may be changed only by an agreement in writing signed by the party against
whom any waiver, change, amendment, modification or discharge may be sought.
14. Assignment. No party to this Agreement may assign any of its
----------
rights or obligations under this Agreement without the prior written consent of
the other party hereto, except that Grantee may assign its rights and
obligations hereunder to any of its direct or indirect wholly owned
subsidiaries, but no such transfer shall relieve Grantee of its obligations
hereunder if such transferee does not perform such obligations.
15. Headings. The section headings herein are for convenience only and
--------
shall not affect the construction of this Agreement.
16. Counterparts. This Agreement may be executed in any number of
------------
counterparts, each of which, when executed, shall be deemed to be an original
and all of which together shall constitute one and the same document.
17. Governing Law; Waiver of Jury Trial. This Agreement shall be
-----------------------------------
governed by and construed in accordance with the laws of the State of Delaware
(regardless of the laws that might otherwise govern under applicable Delaware
principles of conflicts of law). Each of the parties hereto waives any right to
trial by jury with respect to any claim or proceeding related to or arising out
of this Agreement or any of the transactions contemplated hereby.
THE GRANTOR AGREES THAT, IN CONNECTION WITH ANY LEGAL SUIT OR
PROCEEDING ARISING WITH RESPECT TO THIS AGREEMENT, IT SHALL SUBMIT TO THE
JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
AND AGREES TO VENUE IN SUCH COURTS. THE GRANTOR HEREBY APPOINTS THE SECRETARY OF
THE GRANTOR AS ITS AGENT FOR SERVICE OF PROCESS FOR PURPOSES OF THE FOREGOING
SENTENCE ONLY.
18. Termination. The right to exercise the Option granted pursuant to
-----------
this Agreement shall terminate (the "Option Termination Date") at the earlier of
(i) the Effective Time (as defined in the Merger Agreement), (ii) 90 days after
the Merger Termination Date, (iii) six months from the latest date a shareholder
vote occurs or is scheduled and (iv) the termination of the Merger Agreement
under Section 12.1(i); provided that, if the Option cannot be exercised or the
Shares cannot be delivered to Grantee upon such exercise because the conditions
set forth in Section 2(a) or (b) hereof have not yet been satisfied, the Option
Termination Date shall be extended until thirty days after such impediment to
exercise or delivery has been removed.
All representations and warranties contained in this Agreement shall
survive delivery of and payment for the Shares.
19. Profit Limitation. (a) Notwithstanding any other provision of this
-----------------
Agreement, in no event shall Grantee's Total Profit (as hereinafter defined)
exceed $8.366 million
8
<PAGE>
(the "Cap") and, if it otherwise would exceed such amount, Grantee, at its sole
election, shall either (a) deliver to Grantor for cancellation Shares previously
purchased by Grantee, (b) pay cash or other consideration to Grantor or (c)
undertake any combination thereof, so that Grantee's Total Profit shall not
exceed the Cap after taking into account the foregoing actions.
Notwithstanding any other provision of this Agreement, this Option may
not be exercised for a number of Shares as would, as of the date of the Stock
Exercise Notice, result in a Notional Total Profit (as defined below) of more
than the Cap and, if exercise of the Option otherwise would exceed such amount,
Grantee, at its discretion, may increase the Purchase Price for that number of
Shares set forth in the Stock Exercise Notice so that the Notional Total Profit
shall not exceed the Cap; provided, that nothing in this sentence shall restrict
any exercise of the Option permitted hereby on any subsequent date at the
Purchase Price set forth in Section 1(a) hereof.
As used herein, the term "Total Profit" shall mean the aggregate
amount (before taxes) of the following: (i) the amount of cash received by
Grantee pursuant to Section 12.2(b) of the Merger Agreement and Section 1(c)
hereof, (ii) (x) the amount received by Grantee pursuant to Grantor's repurchase
of Shares pursuant to Section 7 hereof, less (y) Grantee's purchase price for
such Shares, and (iii) (x) the net cash amounts received by Grantee pursuant to
the sale of Shares (or any other securities into which such Shares are converted
or exchanged) to any unaffiliated party, less (y) Grantee's purchase price for
such Shares.
As used herein, the term "Notional Total Profit" with respect to any
number of Shares as to which Grantee may propose to exercise this Option shall
be the Total Profit determined as of the date of the Stock Exercise Notice
assuming that this Option were exercised on such date for such number of Shares
and assuming that such Shares, together with all other Shares held by Grantee
and its affiliates as of such date, were sold for cash at the closing market
price for the Common Stock as of the close of business on the preceding trading
day (less customary brokerage commissions).
20. Severability. If any term, provision, covenant or restriction of
------------
this Agreement is held by a court of competent jurisdiction to be invalid, void
or unenforceable, the remainder of the terms, provisions, covenants and
restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.
21. Public Announcement. The Grantee will consult with Grantor and
-------------------
Grantor will consult with Grantee before issuing any press release with respect
to the initial announcement of this Agreement, the Option or the transactions
contemplated hereby and neither party shall issue any such press release prior
to such consultation except as may be required by law or the applicable rules
and regulations of Nasdaq or the NYSE.
9
<PAGE>
IN WITNESS WHEREOF, Grantee and Grantor have caused this Agreement to
be duly executed and delivered on the day and year first above written.
OMNICARE, INC.
By: /s/ Joel F. Gemunder
----------------------------------------
Name: Joel F. Gemunder
Title: President
IBAH, INC.
By: /s/ Geraldine A. Henwood
---------------------------------------
Name: Geraldine A. Henwood
Title: Chief Executive Officer
10
<PAGE>
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
CONTACT FOR OMNICARE: CONTACT FOR IBAH:
Cheryl D. Hodges Neil Lansing II
(513) 762-6967 (215) 283-0770, ext. 2117
Noonan/Russo Communications
Timothy Sipols (media)
(212) 696-4455, ext. 272
Email: [email protected]
OMNICARE TO ACQUIRE IBAH
-- DEAL TO CREATE GLOBAL PLATFORM OF GROWTH
IN CONTRACT RESEARCH SERVICES FOR PHARMACEUTICAL INDUSTRY --
COVINGTON, KENTUCKY AND BLUE BELL, PENNSYLVANIA -- March 31, 1998 --Omnicare,
Inc. (NYSE:OCR) and IBAH, Inc. (NASDAQ:IBAH) today announced the execution of a
definitive agreement under which Omnicare will acquire IBAH, the fifth largest
global contract research organization ("CRO"), in a stock-for-stock merger. In
the merger, each outstanding IBAH common share will be converted into $5.75
market value of Omnicare common shares, subject to the terms of the agreement.
Omnicare expects to issue approximately $169 million in Omnicare stock. The
transaction is structured as a tax-free pooling of interests and, excluding
transaction-related expenses, is expected to be accretive to Omnicare's earnings
per share in 1998.
"With this acquisition, we strengthen and extend the international reach of
Omnicare's contract research services, which will allow us to provide value of
great significance to our strategic partners in the pharmaceutical industry,"
said Joel F. Gemunder, Omnicare president. "This transaction, coupled with our
recent acquisition of Coromed, gives Omnicare the critical mass to be a global
full-service resource for clinical research and development, pharmaceutics, data
management and analysis, and pharmacoeconomics."
Through its partnership with IBAH, Omnicare gains the global infrastructure that
pharmaceutical manufacturers require to conduct major, simultaneous clinical
studies around the world. With more than 900 employees, IBAH operates in the
U.S. and 19 other countries, including Australia, Belgium, Denmark, Finland,
France, Germany, the Netherlands, Spain, Sweden, Switzerland and the United
Kingdom. In addition, IBAH has a strong presence in Eastern Europe and is
currently the sole CRO accredited to operate in Russia.
<PAGE>
"We are excited by the dynamic growth opportunities in the burgeoning $3.5
billion CRO market, which is nearly equal in size to our traditional long-term
care pharmacy market and is growing even more rapidly," added Mr. Gemunder.
"Our merger gives Omnicare access to broad therapeutic expertise gained from
IBAH's successful filing of 50 New Drug Applications (NDAs) in the U.S. and 60
such applications in the international marketplace. With this acquisition,
Omnicare will play an increasingly integral role in helping drug manufacturers
develop, test, and market new and better pharmaceutical therapies."
"Moreover, this further expansion in the CRO business provides Omnicare with the
opportunity to leverage our core strengths and resources. The fast-growing
elderly population is compelling drug manufacturers to focus increasingly on
geriatric pharmaceutical care. Through the day-to-day services we provide to
nearly 470,000 elderly residents at more than 5,700 long-term care facilities,
Omnicare is compiling one or the most comprehensive databases on this population
in the U.S. This, in combination with IBAH's expertise in data management and
biostatistical analysis, will allow us to enhance our expertise in disease and
outcomes management as well as demonstrate the pharmacoeconomic benefit of new
and existing drugs for pharmaceutical manufacturers," said Mr. Gemunder.
"Then too, the company's large and growing base of long-term care facility
clients combined with our ability to efficiently identify patients with existing
disease states and certain risk profiles, has allowed Omnicare to form networks
of nursing facilities able to participate as research sites. With Omnicare's
vast client base, our relationships with physicians and our depth of
understanding of the geriatric population, we can help expedite the research
process, giving us an exclusive advantage in partnering with pharmaceutical
companies in the development of better drugs for the elderly," he added.
"As a result of this merger IBAH will have substantially enhanced financial
resources to accelerate our plan to add more services, expand geographically and
strengthen our data management and information technology capabilities," said
Gerri Henwood, IBAH's chief executive officer. "In addition, IBAH now has
access to a large and unique pool of patient information that comprises more
than 25% of the elderly residents in long-term care facilities. This will add
another important area of therapeutic and population expertise to the portfolio
of skills we bring to client relationships. It opens a major new avenue for
research and enhances the design and development of products which address the
diseases of an aging population. I am excited about our future with Omnicare
and leveraging my team, and that of Omnicare's, to build our business more
rapidly."
The definitive agreement has been approved by both Boards of Directors and is
subject to the approval of IBAH's shareholders, the expiration of the waiting
period under the Hart-Scott-Rodino Anti-Trust Act, and certain other terms and
conditions. In connection
<PAGE>
with this transaction, IBAH has granted Omnicare an option to purchase up to
19.9% of IBAH's common shares exercisable upon the occurrence of certain
circumstances specified in the agreement. It is anticipated that the
transaction will be completed by the end of the third quarter of 1998.
Morgan Stanley & Co. Incorporated and Salomon Smith Barney acted as financial
advisors to Omnicare and IBAH, respectively.
Omnicare, headquartered in Covington, Kentucky, is a leading geriatric
pharmaceutical care company with current annualized revenues of approximately
$1.2 billion. Including its pending acquisition of CompScript, Inc., Omnicare
serves nearly 470,000 residents in more than 5,700 long-term care facilities in
37 states, making it the nation's largest provider of professional pharmacy and
related consulting and data management services for long-term care, assisted
living and other institutional health care facilities. Omnicare also provides
comprehensive clinical research services for the pharmaceutical and
biotechnology industries through its Coromed subsidiary, which offers CRO
services in the United States, Canada and Argentina and employs approximately
150 people.
IBAH, Inc., headquartered in Blue Bell, Pennsylvania, is a worldwide leader in
providing comprehensive product development services to client companies in the
pharmaceutical, biotechnology, medical device and diagnostics industries. As
the fifth largest CRO, IBAH offers services for all stages of drug development,
helping client companies to accelerate products from discovery through
development and commercialization more rapidly and cost-effectively. IBAH's net
revenues are currently running at the annualized rate of approximately $99
million.
For more information on Omnicare, Inc. or IBAH, Inc. via the Internet, including
a full menu of news releases: http://www.businesswire.com/cnn/ocr.htm or
---------------------------------------
www.IBAH.com.
- -------------
Statements in this press release concerning Omnicare's and IBAH's business
outlook or future economic performances, anticipated profitability, revenues,
expenses or other financial items, anticipated cost synergies, economies of
scale and product or service line growth, together with other statements that
are not historical facts, are forward-looking statements that are estimates
reflecting the best judgment of Omnicare and IBAH based on currently available
information. Such forward-looking statements involve risks, uncertainties and
other factors that could cause results to differ materially from those stated.
These include trends for the continued growth of the businesses of Omnicare and
IBAH, the realization of anticipated revenues, profitability and costs synergies
of the combined companies, and other risks and uncertainties described in
Omnicare's and IBAH's reports and filings with the Securities and Exchange
Commission. There can be no assurance that such factors will not affect the
accuracy of such forward-looking statements, and neither Omnicare nor IBAH
assumes any obligation to update the information on this release.
# # #
